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There is increasing evidence that the mechanisms of drug resistance in Mycobacterium 
tuberculosis are not limited to mutations in the known drug resistance causing genes. 
Classically a mutation in one gene confers resistance to a drug, for example a mutation in the 
rpoB gene confers rifampicin resistance. However varying levels of resistance and fitness 
observed, as well as the lack of mutations in some clinically resistant isolates has guided 
researchers to focus on alternate genetic and physiological factors influencing drug resistance 
in M. tuberculosis. Whole genome sequencing (WGS) has previously identified 
polymorphisms in the rpoC gene of M. tuberculosis which were later confirmed to compensate 
for the loss of fitness occurring with the acquisition of rpoB mutations. Similarly, numerous 
mutations have been identified to be ancillary to drug resistance. Additionally, WGS has been 
used to investigate the evolution of drug resistance in M. tuberculosis. In addition to genetic 
factors, the activity of energy dependent efflux pumps has been associated with drug resistance 
and has been demonstrated to provide low levels of drug resistance to anti-TB drugs to allow 
for the development of drug resistance causing mutations. This study aimed to further 
investigate both genetic and efflux based mechanisms of resistance in M. tuberculosis, as well 
the response of M. tuberculosis to rifampicin exposure. It was therefore hypothesised that M. 
tuberculosis acquires additional genomic mutations during the evolution of rifampicin mono-
resistance to multidrug resistant (MDR). In addition this study hypothesised that efflux pump 
activity contributes to the level of rifampicin resistance in M. tuberculosis, and this activity is 
dependent on the presence of specific rpoB mutations. Lastly, this study hypothesised that 
rifampicin exposure induces the expression of energy metabolism genes and efflux pumps in 
M. tuberculosis.  
The Department of Biomedical Sciences strain bank was interrogated and a total of 6 clinical 
isolates originating from 3 patients representing evolution from rifampicin mono-resistance to 
MDR were selected for WGS analysis. WGS identified novel genetic variants occurring during 
the evolution of drug resistance. Numerous variants were only present in a proportion of the 
population and were observed to change (emerge or disappear) during the course of treatment. 
This heterogeneity suggests that M. tuberculosis populations are dynamic during the evolution 
of drug resistance, accumulating numerous genetic changes.  




Experiments investigating the role of efflux pump activity in rifampicin resistance 
demonstrated that efflux pump activity differs in M. tuberculosis isolates with an rpoB 
Ser531Leu mutation compared to those with an rpoB His526Leu mutation. In addition, the 
efficacy of verapamil as an efflux pump inhibitor differed between these isolates. This finding 
may have implications for the consideration of the inclusion of efflux pump inhibitors in 
treatment regimens. 
Lastly, this study is the first to identify mmpL5 expression in response to rifampicin exposure; 
however the consequence of this association remains unknown. An additional finding of the 
investigation into the response of M. tuberculosis to rifampicin exposure is the identification 
of a proposed transcriptional regulator responding to rifampicin exposure. Together these 
findings demonstrate the numerous genetic and physiological mechanisms contributing to drug 










Toenemde bewyse stel voor dat meganismes van weerstandigheid in Mycobacterium 
tuberculosis is nie beperk tot slegs mutasies in gene wat bekend is vir die oorsaak van 
middelweerstandigheid nie. Dit word algemeen aanvaar dat ‘n mutasie in een geen 
weerstandigheid teen n middel veroorsaak, byvoorbeeld ‘n mutasie in die rpoB geen veroorsaak 
rifampisien weerstandigheid. Daar is egter al waargeneem dat verskillende vlakke van 
weerstandigheid en fiksheid voorkom, asook die afwesigheid van mutasies in sommige kliniese 
middelweerstandige isolate. Dit het navorsers gelei om te fokus op alternatiewe genetiese en 
fisiologiese faktore wat weerstandigheid in M. tuberculosis kan beЇnvloed. Mutasies in rpoC 
is voorheen geïdentifiseer deur heelgenoom volgorde bepaling en is later bevestig om 
vergoedend te wees vir die afname in fiksheid as gevolg van die verwerwing van rpoB 
mutasies. Soortgelyk is dit ook gevind dat verskeie mutasies aanvullend is tot middel 
weerstandigheid. Verder is heelgenoom volgorde bepaling ook gebruik om die evolusie van 
middelweerstandighein in M. tuberculosis te bestudeer. Ten spyte van genetiese faktore, is daar 
ook gevind dat die aktiwiteit van energie afhanklike uitvloei pompe geassosieer is met middel 
weerstandigheid en daar is gewys dat dit n verlaagde vlak van weerstandigheid voorsien sodat 
middel weerstandige mutasies kan ontwikkel. Hierdie studie stel ten doel om beide die 
genetiese en uitvloei pomp meganismes van weerstandigheid in M. tuberculosis verder te 
ondersoek, asook die reaksie van M. tuberulosis op rifampisien blootstelling. Hierdie studie 
het uit drie aparte navorsing vrae bestaan om die volgende hipoteses aantespreek: M. 
tuberculosis verkry additionele genomiese mutasies gedurende die evolusie van rifampisien 
enkel weerstandigheid na meervoudige middelweerstandigheid (MDR); dat uitvloei pompe 
bydra tot die vlakke van rifampisien weerstandigheid in M. tuberculosis en dat hierdie 
aktiwiteit  afhanklik is van spesifieke rpoB mutasies; dat die blootstelling van M. tuberculosis 
aan rifampisien lei tot die verhoging in geen uidrukking van energie metabolisme en uitvloei 
pompe. 
Die departement van Biomediese Wetenskappe se isolaat versameling is ondersoek en n totaal 
van ses kliniese isolate afkomstig van drie pasiënte wat die evolusie van rifampisien enkel 
weerstandigheid na MDR voorstel is met heelgenoom volgorde bepaling ondersoek. 
Heelgenoom volgorde bepaling het nuwe genetiese variante geïndentifiseer tydens die evolusie 
van weerstandigheid. Verskeie variante was slegs teenwoordig in n gedeelte van die populasie 




wat verander het (verskyn of verdwyn) tydens die behandelingskursus. Hierdie heterogenetiese 
eienskappe stel voor dat M. tuberculosis populasies dinamies is gedurende die evolusie van 
middel weerstandigheid deur die akkumulering van verskeie genetiese verandering.  
Eksperimente wat die rol van uitvloei pomp aktiwiteit in rifampisien weerstandiheid ondersoek 
het gewys dat uitvloei pomp aktiwiteit verskil tussen M. tuberculosis isolate met rpoB 
Ser531Leu en rpoB His526Leu mutasies. Verder was die effektiwiteit van verapamil as uitvloei 
pomp inhibeerder verskillend tussen hierdie isolate. Hierdie bevinding mag dalk implikasies 
inhou  vir die oorweging om uitvloei pomp inhibeerders intesluit by behandelingskursusse.  
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South Africa is ranked by the World Health Organisation (WHO) as having one of the highest 
incidences of Tuberculosis (TB) globally, with a reported incidence of 1003 cases per 100 000 
population in South Africa in 2012 (1). The emergence of drug resistance is an increasing 
problem which negatively impacts on the TB control program. The WHO 2013 Global 
Tuberculosis Control Report estimates that in South Africa there were approximately 4600 new 
cases of multi-drug resistant (MDR) TB (resistant to at least isoniazid and rifampicin) and 3500 
retreatment cases of MDR (2), indicating a high rate of treatment failure. Treatment success 
rates are below 50% for MDR-TB with poorer outcomes for extensively drug resistant (XDR)-
TB (75% mortality over a 5 year period) (2). Conventionally, drug resistance in Mycobacterium 
tuberculosis, the causative agent of TB, has been associated with mutations in specific target 
genes followed by antibiotic selection during periods of poor adherence. For example, 
mutations in the Rifampicin Resistance Determining Region (RRDR) of the rpoB gene have 
been associated with rifampicin resistance (3, 4). However, mutations in known drug resistance 
causing genes are not the sole mechanisms of drug resistance. For example, only 95% of 
clinical M. tuberculosis isolates resistant to rifampicin harbour an rpoB mutation (5). Therefore 
the possibility of alternate mechanisms contributing to drug resistance in M. tuberculosis needs 
to be explored.  
Numerous approaches have been followed to identify novel mechanisms of drug resistance, or 
mechanisms which may be contributing to the level of drug resistance in M. tuberculosis. 
Efflux has largely been investigated for its role in defining the level of drug resistance, as well 
as its role in mechanisms of drug tolerance (6–13). In addition, it has been shown that the 
activation of efflux pumps may act as an initial gateway mechanism enabling acquisition of 
resistance causing mutations (14). Although efflux has been widely recognised to contribute to 
the problem of drug resistance, it has recently been highlighted that there is no evidence that 
efflux pump activity may be the sole cause of clinical drug resistance (14, 20). Numerous 
studies have shown the success of including efflux inhibitors in treatment regimens to improve 
the outcome of anti-TB therapy (15–18). 
Despite the role of efflux and the success of efflux pump inhibitors as a complementary 
treatment to current and new regimens, other mechanisms contributing to resistance have also 
been investigated. Whole genome sequencing (WGS) has successfully been used to investigate 
compensatory mutations, as well as novel mutations conferring drug resistance (19–23).  In 
addition, mutations thought to be ancillary to drug resistance have also been identified in a 




number of studies (14). WGS techniques have also allowed for investigation into genetic 
diversity in M. tuberculosis, during the course of infection in single isolates as well as between 
numerous samples within an outbreak (14, 24–26). Investigation into strain diversity has 
highlighted the implications of genetic diversity in the development on new rapid diagnostic 
techniques (27, 28). These findings demonstrate the importance of identifying and studying 
sub-populations within patients at different time points, as well as investigating the genomic 
occurrences during the evolution of drug resistance.   
While WGS is increasingly being used to investigate drug resistance and evolution in M. 
tuberculosis, there is still little known about genomic changes that occur during the evolution 
of drug resistance, beyond the known drug resistance causing mutations. In addition, little 
research has focused on the physiological consequences of specific mutations as well as the 
transcriptional response of M. tuberculosis to drug exposure. This study aims to utilise WGS 
to investigate novel mechanisms contributing to the evolution of drug resistance, as well as use 
efflux pump activity assays and gene expression analysis to investigate metabolic changes 
which may be involved in drug resistance in M. tuberculosis.  
The overall aim of this study is therefore to further investigate mechanisms contributing to drug 
resistance, with a specific focus on rifampicin resistance. Investigation into mechanisms 
contributing to drug resistance was carried out in three independent chapters. The study is 
structured as follows: 
 Chapter 2 reviews literature and discusses the role of energy metabolism and efflux 
pumps in drug resistance in M. tuberculosis.  
 Chapter 3 describes the methods used in Chapters 4, 5 and 6. 
 In Chapter 4, WGS of serial M. tuberculosis isolates was used to investigate the in vivo 
evolution of drug resistance from rifampicin mono-resistance to MDR.  
 Chapter 5 focuses on the role of efflux pumps in drug resistance in M. tuberculosis, 
with specific focus on the role of different rpoB mutations on the response of M. 
tuberculosis to verapamil treatment.  
 Chapter 6 investigates the response of M. tuberculosis to rifampicin exposure, focusing 
on the transcriptional response of efflux pumps and components involved in energy 
metabolism in M. tuberculosis.  
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Abstract 
The inherent drug susceptibility of microorganisms is determined by multiple factors, including 
growth state, the rate of drug diffusion into and out of the cell, and the intrinsic vulnerability 
of drug targets with regard to the corresponding antimicrobial agent. Mycobacterium 
tuberculosis, the causative agent of tuberculosis (TB), remains a significant source of global 
morbidity and mortality, further exacerbated by its ability to readily evolve drug resistance. It 
is well accepted that drug resistance in M. tuberculosis is driven by the acquisition of 
chromosomal mutations in genes encoding drug targets/promoter regions; however, a 
comprehensive description of the molecular mechanisms that fuel drug resistance in the clinical 
setting is currently lacking. In this context, there is a growing body of evidence suggesting that 
active extrusion of drugs from the cell is critical for drug tolerance. M. tuberculosis encodes 
representatives of a diverse range of multidrug transporters, many of which are dependent on 
the proton motive force (PMF) or the availability of ATP. This suggests that energy metabolism 
and ATP production through the PMF, which is established by the electron transport chain 
(ETC), are critical in determining the drug susceptibility of M. tuberculosis. In this review, we 
detail advances in the study of the mycobacterial ETC and highlight drugs that target various 
components of the ETC. We provide an overview of some of the efflux pumps present in M. 




tuberculosis and their association, if any, with drug transport and concomitant effects on drug 
resistance. The implications of inhibiting drug extrusion, through the use of efflux pump 
inhibitors, are also discussed.  
Introduction 
Tuberculosis (TB), caused by Mycobacterium tuberculosis, remains a global health problem, 
causing 8.8 million incident cases and 1.1 million deaths in 2012 (1, 2). In many countries, the 
TB epidemic continues unabated in the face of combination chemotherapy which involves the 
administration of at least four drugs. The most significant barrier to the eradication of TB is 
the rapid emergence of multi-drug-resistant (MDR) and extensively drug-resistant (XDR) TB, 
which has rendered current treatments ineffective and placed an enormous patient management 
burden on TB control programs. Treatment of drug-resistant TB is costly and requires the use 
of highly toxic drugs, leading to numerous side effects. Moreover, the spread of MDR strains 
makes for an alarming situation which provides an ideal breeding ground for further, more 
advanced forms of drug resistance (3). Given the limited number of anti-TB drugs currently 
available and the duration of treatment required to achieve cure, there is a global need for the 
discovery of novel drugs with rapid sterilizing activity against active and dormant bacteria. 
These drugs should ideally shorten treatment duration and reduce the pill burden (2, 4). 
Moreover, maintaining the fidelity of the current antibiotics and further understanding the 
mechanism of emergence of drug resistance require immediate attention to address this 
growing problem.  
Suboptimal intracellular concentrations of drugs often lead to transient drug tolerance, which 
may be a precursor to chromosomally encoded, stable drug resistance. There is a growing body 
of evidence that suggests that M. tuberculosis retains the capacity to extrude drugs from the 
cell, resulting in drug tolerance effects (reviewed in reference 5). In many cases, these 
processes are postulated to be dependent on the proton motive force (PMF) and the presence 
of sufficient ATP concentrations within the cell. This suggests that the activity of the 
mycobacterial electron transport chain (ETC) under different conditions plays a key role in 
determining the inherent susceptibility of M. tuberculosis to various drugs. In this review, we 
provide an overview of the mycobacterial ETC and discuss this component of M. tuberculosis 
metabolism as a target for novel antitubercular agents. We also highlight the importance of 
energy metabolism in mediating drug tolerance through efflux.  




The mycobacterial ETC 
In bacteria, the ETC is integrally involved in the generation of energy via oxidative 
phosphorylation. The mycobacterial components involved in oxidative phosphorylation and 
energy production have been extensively reviewed, and the reader is referred to these for more-
detailed information (6–12). Electrons enter and are shunted through the ETC in a variety of 
ways, depending on the source of growth substrates and the availability of terminal electron 
acceptors. Under aerobic conditions, oxygen is used in the final electron transfer steps, and 
under anaerobic conditions, nitrate or fumarate can be used (Figure 2.1). Electron transport in 
mycobacteria is initiated through the activity of various NADH dehydrogenases (NDH) and 
succinate dehydrogenases (SDH), which transfer electrons to menaquinone, a lipophilic redox 
carrier (7, 13, 14). Electrons are then passed to various cytochrome oxidases, which are 
dependent on oxygen availability (Figure 2.1) (7, 15, 16). Of particular note is the fact that the 
mycobacterial ETC, like many bacterial ETCs, is branched and displays an extensive capacity 
to utilize numerous electron donors and acceptors for adapting to decreasing levels of oxygen 
tension and the availability of different reducing equivalents. The roles of various components 
of the ETC are detailed below.  
  







































NDH-1 F0F1-ATP synthaseNDH-2 Cytochrome bc1-aa3
super complex
a) bc1 cytochrome reductase

























Figure 2.1 The mycobacterial electron transport chain. Proposed aerobic and hypoxic/anaerobic pathways are shown (7, 9). NDH-1, NDH-2, and succinate 
dehydrogenase (SDH) are electron donors which reduce menaquinone (MK) to menaquinol (MKH2). Subsequently, MKH2 becomes oxidized, transferring 
electrons to the terminal electron acceptors through the activity of cytochrome oxidases, nitrate reductase (NR), and fumarate reductase (FR). ATP production 
via the F1F0-ATP synthase is fuelled by translocation of protons (H+). The F1F0-ATP synthase consists of two regions, namely, the hydrophobic integral 
membrane region (F0) composed of 3 subunits designated a, b, and c and the hydrophilic region (F1), which extends into the cytoplasm and is composed of 5 
subunits designated α, β, δ, γ, and ε (7, 45–47). Energy production may be targeted by anti-TB compounds at multiple points involved in ATP synthesis as 
shown. These include the transmembrane proton gradient (ΔpH)—targeted by compounds such as nigericin, nisin, lacticin 3147, valinomycin, and pyrazinamide 
(PZA), resulting in disruption of ATP homeostasis. Compounds resulting in a depletion of the ATP pool include phenothiazines, ionophores (shown in the 
diagram), PA-824, benzimidazoles, thiophene, and imidazopyridines (Q203)/bedaquiline—through direct/indirect effects on the ETC. Other components of 
energy metabolism targeted by compounds include NDH-2 (thioridazine and phenothiazine), SDH (thioridazine, phenothiazine, triclosan, and azoles), MK 
biosynthesis (carbamates), Q203, and the F1F0-ATP synthase (bedaquiline). Vertical red arrows indicate proton pumping components of the ETC that directly 
translocate protons into the extracellular matrix.  
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Analysis of the genome sequence of M. tuberculosis H37Rv reveals two types of NDHs in 
mycobacteria, namely, type I NDH (NDH-1), encoded by the nuoABCDEFGHIJKLMN 
operon, and type II NDH (NDH-2), encoded by either the ndh gene or the ndhA gene (17, 18). 
In mycobacteria, the reduction in expression of nuoB, encoding a subunit of NDH-1, during 
oxygen deprivation suggests that NDH-1 is required preferentially under aerobic conditions 
(19), while use of NDH-2 is favoured under anaerobic/nonreplicating conditions (20). 
Treatment of mycobacteria with NDH-2-specific inhibitors, such as trifluoperazine, results in 
blockage of initiation of the ETC under anaerobic conditions, implying that NDH-2 is the 
dominant NDH involved in anaerobic respiration under the conditions tested (20). However, 
the dispensability of the entire nuoABCDEFGHIJKLMN operon under aerobic conditions 
(20) suggests that NDH-2 can operate as an electron donor irrespective of oxygen availability. 
The NuoG subunit of NDH-1 has been identified in a forward genetic screen to be essential for 
inhibiting macrophage apoptosis and in virulence in the murine model of TB infection (21). 
The precise mechanism of apoptosis inhibition is not yet understood, but more-recent work 
suggests that it involves the neutralization of NOX2-derived reactive oxygen species (22). In 
this regard, the suppression of apoptosis leads to reduced distribution of tubercle bacilli 
between cells found within the lung and this results in decreased proliferation of M. 
tuberculosis-specific naive T cells (23). Transposon mutagenesis has identified NDH-1 to be 
dispensable for growth in vitro, and in this context, the apparent essentiality of NuoG for 
macrophage apoptosis does not seem to be directly related to its role in energy metabolism 
(24). Saturating transposon mutagenesis predicts that NDH-1 and NDH-2 are dispensable for 
growth of M. tuberculosis in vitro (24). Furthermore, an ndhA mutant is able to colonize 
mouse lungs, confirming that this enzyme is not essential for pathogenesis (25).  
SDH, or succinate:menaquinone oxidoreductase, is another enzyme responsible for the 
donation of electrons to the quinone pool (13). Transposon mutagenesis confirmed that SDH 
is essential for survival of M. tuberculosis in vitro (24). This enzyme predominantly acts in 
the citric acid cycle, where it oxidizes succinate to fumarate, thereby donating electrons to the 
quinone pool (26, 27). It has been recently demonstrated that, through remodelling of the 
tricarboxylic acid cycle, the activity of SDH is essential for the metabolic adaptation to 
hypoxia, maintenance of membrane potential, and ATP synthesis, indicating that this is a key 
enzyme for persistence and therefore represents a potential new drug target (27).  





Quinones are lipid soluble electron carriers that are responsible for the transfer of electrons 
between the components of the ETC (7, 28). In mycobacteria, the predominant quinones are 
menaquinones (MK), in contrast to the case in Escherichia coli, which utilizes both 
menaquinone and ubiquinone (14, 29–31). In M. tuberculosis, MK is synthesized from the 
precursor chorismate through a series of reactions catalyzed by enzymes encoded by the 
menABCDEFG operon. Recently, an array of MenA inhibitors which display bactericidal 
activity against nonreplicating M. tuberculosis was developed (32). These observations suggest 
that MK needs to be continuously resynthesized to maintain membrane potential. Of the 
compounds developed, carbamates have shown significant bacteriostatic activity against 
nonreplicating M. tuberculosis (Figure 2.1) (32). Due to the importance of the MK pool in 
maintaining the ETC and subsequent ATP synthesis, this biosynthetic pathway represents an 
important target for anti-TB drug design.  
Electron acceptors 
Electrons from reduced menaquinol can be transferred to either of two terminal oxidases: (i) 
the cytochrome bd-type menaquinol oxidase or (ii) the aa3-type cytochrome c oxidase (via the 
cytochrome bc1 reductase complex). It has been suggested that the mycobacterial aa3-type 
cytochrome c oxidase and cytochrome bc1 reductase form a supercomplex (7, 16). The M. 
tuberculosis genome encodes a putative cytochrome bd oxidase which, in Mycobacterium 
smegmatis, has been shown to play an important role in the adaption to a reduced oxygen 
environment (15, 17). The M. tuberculosis genome also encodes a membrane-bound 
respiratory/assimilatory narGHI-encoded nitrate reductase (NR) which is responsible for 
nitrate-associated respiration and assimilation (17, 33–36). Analysis of clinical M. tuberculosis 
isolates revealed that NarG plays an important role in fitness in macrophages (37), consistent 
with the detection of transcripts from this operon within granulomas from lungs of TB patients 
(38) and in the guinea pig model of TB infection (39). The NR is also required for survival of 
M. tuberculosis in vitro under anaerobic conditions of nonreplicating persistence (40) and for 
the protection of M. tuberculosis against acidic conditions during hypoxia (41). These data 
suggest that respiration using nitrate may be an important mechanism for adaption under 
various conditions of stress. In support of this hypothesis, the nirBD-encoded nitrite reductase 
has recently been shown to play an important role in nonreplicating persistence of M. 
tuberculosis (34, 42). Considering other alternate electron acceptors, transcriptional analysis 




revealed that frdA, a gene encoding the flavoprotein subunit of the fumarate reductase, is 
upregulated under hypoxic conditions in M. tuberculosis and plays a vital role in maintenance 
of an energized membrane (43).  
ATP synthesis and the F1F0-ATP synthase  
Substrate-level phosphorylation involves the production of ATP by the utilization of free 
energy produced during various steps in metabolic pathways and provides a fast source of ATP 
through a process that is not dependent on external electron acceptors (44). In contrast, during 
oxidative phosphorylation, ATP is produced through the activity of the F1F0-ATP synthase 
enzyme, which is coupled to the PMF. M. tuberculosis has been classified as an obligate 
aerobe; as such, it would be dependent on oxidative phosphorylation for growth and survival 
during pathogenesis. The structure of F1F0-ATP synthase in various prokaryotes is conserved 
and consists of two regions, namely, the hydrophobic integral membrane region (F0) and the 
hydrophilic region (F1), extending into the cytoplasm (Figure 2.1) (45–47). The F0 region is 
composed of 3 subunits designated a, b, and c, whereas the F1 region is composed of 5 subunits 
designated α, β, δ, γ, and ε (45, 46). ATP is synthesized by the α3β3-hexamer through rotation 
of the γ-ε pair (48). Rotation of subunits ε and γ is coupled to rotation of the c-ring upon proton 
translocation (Figure2.1) (48, 49). The mycobacterial F1F0-ATP synthase is encoded by a single 
operon, Rv1303-atpBEFHAGDC-Rv1312 (17). Recently, BlaI (Rv1846c) was identified as 
a transcriptional regulator of this operon (50). Treatment with ATP synthase inhibitors results 
in increased expression of blaI, suggesting a role for this regulator in response to stress (51). 
The mode of regulation of blaI in Staphylococcus aureus has been elucidated. BlaI has a 
structure that is similar to that of penicillin binding proteins and is able to act as a transcriptional 
repressor in response to antibiotic treatment (52). In this regard, it has been shown that BlaI 
(Rv1846c) in M. tuberculosis responds to antibiotic treatment and is released from its cognate 
operator sequences to allow gene expression (50). BlaR (Rv1845c), a zinc-dependent 
metalloprotease, has been hypothesized to play a role in cleaving itself and BlaI during 
derepression of the operon (50, 52). More recently, transcriptional regulators Rv1773c and 
Rv3405c have been identified as regulators for Rv1303, the first gene of the atpBEFHAGDC 
operon (53).  
 
 




Drugs that target the ETC 
Recent drug discovery efforts have led to numerous compounds which have shown great 
promise in the treatment of TB due to their ability to eliminate M. tuberculosis in various 
preclinical models and early clinical trials. Among these is the discovery of TMC207 
(bedaquiline), which kills M. tuberculosis by inhibition of the membrane-bound F1F0-ATP 
synthase complex, resulting in depletion of cellular ATP levels and eventual death of the 
organism (49, 54–56). Use of this drug, commonly known as bedaquiline, resulted in decreased 
time to smear conversion during a phase IIb randomized trial (54, 57). Bedaquiline kills M. 
tuberculosis by interacting with the hydrophobic region of subunit c, as well as with subunit ε 
(48), of the F1F0-ATP synthase and does not cross-react with the human ATP synthase complex 
(56, 58). Inhibition of c-ring rotation due to disruption in the c-ring:ε subunit interaction results 
in inhibition of ATP production and subsequent cell death (48). The efficacy of bedaquiline in 
clinical trials confirms that targeting energy metabolism during TB infection may be promising, 
particularly for nonreplicating organisms, as there is documented evidence that ATP is essential 
for the viability of nonreplicating persistent mycobacteria (20, 55, 59). Moreover, the ability to 
eliminate subpopulations of persisting organisms provides an opportunity for tissue 
sterilization, thereby minimizing the risk for recrudescent disease through reactivation of 
persisting bacteria. The ability of these organisms to maintain an energized membrane potential 
in the face of prolonged quiescence is critical to their survival and highlights the importance of 
understanding the physiology of M. tuberculosis with regard to energy metabolism (9). In this 
context, ATP synthesis has become a focus area for the identification of new drug targets in 
mycobacteria (60).  
The PMF is an important aspect in the final production of ATP via the F1F0-ATP synthase (20). 
The PMF is established through the development of the transmembrane proton gradient (ΔpH) 
which occurs when electrons move through the ETC and results in the establishment of 
membrane potential (Δψ) (reviewed in references 6 and 7). The proton gradient generated 
through oxidative phosphorylation drives ATP synthesis via the F1F0-ATP synthase which is 
responsible for the conversion of the electrochemical potential energy generated by the PMF 
into chemical energy in the form of ATP (45). Since oxidative phosphorylation is the main 
source of energy production in mycobacteria, ATP synthase represents the key enzyme 
involved in ATP production in mycobacteria.  




Studies of valinomycin and nigericin treatment (inhibitors of Δψ and ΔpH, respectively) 
revealed that in both actively replicating and hypoxic nonreplicating bacilli, death occurs via 
decreased ATP levels in a dose-dependent manner (20). Nisin, a lantibiotic produced by 
Lactococcus lactis, has been shown to dissipate Δψ and ΔpH, thereby disrupting energy 
metabolism (20, 61). Lantibiotics such as nisin and lacticin 3147 form pores in the 
mycobacterial cell membrane which result in dissipation of Δψ (Figure 2.1) (several studies 
have investigated the effect of these compounds in mycobacteria [61–65]). Although nisin is 
able to dissipate the membrane potential and decrease ATP levels in mycobacteria, the MIC 
values for various mycobacterial strains are very high and not comparable to those of current 
anti-TB drugs (62). This poor inhibitory activity of nisin has been attributed to its low solubility 
at pH 7, in contrast to lacticin 3147, which is soluble under such conditions and demonstrates 
greater activity against mycobacteria, thus warranting further investigation as a potential anti-
TB drug (62). Another compound shown to target Δψ is pyrazinamide (PZA), where treatment 
results in a decrease in ATP levels, most likely the resulting effect of diminished membrane 
potential (66). Unlike current first- and second-line anti-TB drugs, PZA has been shown to be 
active against both replicating and nonreplicating mycobacteria (67). This was highlighted in 
a recent study, where nutrient-starved M. tuberculosis displayed increased susceptibility to 
PZA due to the decreased membrane potential (68). Furthermore, PZA treatment of mice 
infected with M. tuberculosis significantly reduces the release of proinflammatory cytokines 
and chemokines, suggesting that PZA has important host-directed effects (69).  
Due to the importance of ATP for cellular viability, the components involved in the process of 
ATP production represent viable drug targets which, in combination with current anti-TB 
drugs, could be used for effective treatment. A number of existing compounds deplete cellular 
ATP levels and have subsequent bactericidal effects on replicating and nonreplicating 
mycobacteria (Figure 2.1). These compounds include n-decanesulfonylacetamide (DSA) and 
nisin. DSA is the lead compound of the β-sulfonylacetamide class of antimicrobials and has 
been shown to be active in vitro against replicating M. tuberculosis as well as against anaerobic 
M. bovis BCG (70–73). It has been proposed that DSA interferes with components of the 
respiratory chain, thereby disrupting energy metabolism (73).  
Another compound targeting energy metabolism is PA-824, which is currently in human 
clinical trials as an anti-TB drug (57, 74–76). PA-824, a bicyclic nitroimidazole, has the ability 
to kill both replicating and hypoxic, nonreplicating M. tuberculosis through a multifaceted 




mechanism that involves inhibition of mycolic acid biosynthesis and respiratory poisoning 
through intracellular release of nitric oxide, which is postulated to inhibit the final stages of 
electron transfer in cytochrome c oxidase (76).  
More recent efforts have yielded a novel class of imidazo[1,2-a]pyridine amide (IPA) 
compounds (77, 78) that prevent proliferation of M. tuberculosis by inhibition of the 
cytochrome bc1 reductase complex in the mycobacterial respiratory chain (77, 79) (Figure 2.1). 
These compounds bind the QcrB subunit and induce bacterial cell death by abrogating electron 
flow through the ETC, resulting in reduced ATP synthesis under aerobic and anaerobic 
conditions (79). Two independent studies identified QcrB as the target for IPAs through the 
generation of spontaneous resistant mutants carrying various substitutions at the Thr313 
residue (77, 79). The lead compound from this series, Q203, displays potent killing of M. 
tuberculosis in axenic culture, in macrophages, and in the murine model of TB infection, with 
a spontaneous mutation rate in the order of 10−8 (79). Q203 is well tolerated in mice and now 
awaits further analysis in clinical trials.  
Phenothiazines, such as chlorpromazine and thioridazine (THZ) (Figure 2.1), are a group of 
clinically relevant compounds that are predicted to target the ETC through inhibition of NDH-
2 (18). THZ is an old neuroleptic agent that has demonstrated activity in killing drug-
susceptible and drug-resistant M. tuberculosis in various model systems in vitro and ex vivo 
and in the murine model of TB infection (80–84). In the promising development, THZ 
demonstrated therapeutic benefit in treatment of XDR-TB patients in Argentina and is currently 
being used in trials in India (reviewed in reference 85). In a recent study, THZ activity was 
shown to be independent of the bacterial growth phase; i.e., THZ is effective against actively 
replicating bacilli, semi-dormant bacilli, and nonreplicating persisters (86). That study also 
demonstrated a low mutation frequency in M. tuberculosis, suggesting a delay in the 
development of THZ resistance (86). While retaining the ability to inhibit the ETC in 
mycobacteria, THZ also has the potential to directly inhibit efflux of drugs (87). In addition to 
phenothiazines, which target the mycobacterial NDH-2, clofazimine (CFZ)—a 
rhiminophenazine—is subject to reduction by NDH-2 and, upon subsequent oxidation, leads 
to the formation of reactive oxygen species (88), which presumably contributes to its efficacy 
in mice (89).  
Numerous studies have investigated the efficacy of novel combinations of drugs by 
incorporating new and existing compounds which have demonstrated activity against bacterial 




targets involved in energy metabolism. These combinations have demonstrated efficacy that is 
comparable or enhanced in comparison to the current anti-TB regimens, and the potential to 
shorten the current treatment period has been highlighted. A recent 14-day early bactericidal 
activity (EBA) study demonstrated the benefit of adding PA-824 to a regimen containing 
moxifloxacin (MXF) and PZA to shorten treatment duration (89). Bedaquiline–PZA–PA-824 
and bedaquiline–PA-824–MFX combinations have demonstrated greater efficacy than 
rifampin (RIF)-isoniazid (INH)-PZA in reducing CFU (90). Tasneen et al. also demonstrated 
that drug combinations containing bedaquiline showed higher efficacy with respect to relapse 
prevention in a mouse model (89). In a separate study, numerous combinations of bedaquiline, 
PA-824, CFZ, and PNU-100480 were shown to be more effective than a RIF-INH-PZA 
combination (90).  
Energy metabolism and drug efflux 
Active transport of drugs and xenobiotics through the activity of efflux pumps (EPs) is well 
documented in bacteria and points to an important role for this process in phenotypic drug 
tolerance and the subsequent emergence of drug resistance due to reduced intracellular drug 
concentrations (5). A key feature of these systems is their dependence on the PMF or the 
availability of ATP, which inextricably links drug efflux to energy metabolism and the ETC 
(5, 91, 92). EPs adopt a diversity of structures in bacteria and can be classified into different 
families based on overall secondary structure and the molecules transported. These include, 
but are not limited to, the major facilitator superfamily (MFS), small multi-drug resistance 
(SMR) family, resistance/nodulation/cell division (RND) family, the ATP-dependent ABC-
type superfamily of transporters, and the multidrug and toxic compound extrusion (MATE) 
family (91, 93, 94).  
The widely distributed P-glycoprotein, encoded by the mdr gene, is one of the first ABC-type 
transporters implicated in drug efflux and has been implicated in the extrusion of numerous 
drugs in different organisms (91). The members of this family of transporters require the energy 
of ATP hydrolysis for active efflux of drugs (Figure 2.2) (95, 96). In contrast, the MFS, SMR, 
RND, and MATE-type EPs require an energized membrane and the PMF (ΔpH and ΔΨ) for 
activity (reviewed in reference 91). The pumps often operate as drug-metabolite/proton 
symporters, antiporters, or uniporters. Schematic representations of these EPs are shown in Fig. 
2. The MFS-type EPs can be characterized into 6 evolutionarily related subfamilies, including 
those containing 14 or 12 transmembrane segments, sugar importers, phosphate ester 
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antiporters, and other transporters (97–99). It has been proposed that these large membrane-
associated proteins have evolved via intragenic tandem gene duplication to give rise to a widely 
distributed, structurally diverse family of proteins (97). MFS EPs require the presence of 
protons in the periplasm and couple efflux with proton translocation to the cytoplasm (100) 
(Figure 2.2). However, these systems differ in their dependence on the ΔpH and ΔΨ; for 
example, the bmr-encoded multidrug EP in Bacillus subtilis requires a strong ΔpH to drive the 











Figure 2.2 Efflux pumps in M. tuberculosis. The EPs dependent on the PMF and ATP are shown. The 
mycobacterial ETC generates a transmembrane proton gradient (ΔpH) resulting in membrane potential 
(Δψ); ΔpH and Δψ together constitute the PMF. Protons translocated into the pseudoperiplasmic space 
are used by EPs to extrude drugs. The major facilitator superfamily (MFS) EPs are made of integral 
membrane proteins with 12 to 14 transmembrane regions, while the small multidrug resistance (SMR) 
EPs contain 4 to 6 transmembrane domains. Both systems use protons from the periplasm, and the 
members differ in their requirements for ΔpH and Δψ (see the text for details). The resistance 
nodulation/cell division (RND) EPs are also integral membrane proteins, and members of this family 
from Gram-negative bacteria associate with other proteins to form a multisubunit complex that spans 
both the inner and outer membranes. Hence, there is a possibility that a similar structure occurs in 
mycobacteria, where the members of this group of EPs span the pseudoperiplasmic space and associate 




with the mycolic acid (MA) layer, possibly through OmpA (outer membrane protein A)-like 
homologues. RND proteins also require protons—although these may originate from outside the cell—
and the PMF. ABC transporters require ATP for the active drug extrusion and, as such, are also 
dependent on energy production in the cell. Not shown in the figure are the members of the fifth class 
of EPS, termed the multidrug and toxic compound extrusion (MATE) proteins; while some of these are 
dependent on PMF and protons, the majority of characterized members operate via sodium influx (93). 
The Smr staphylococcal multidrug efflux protein and E. coli EmrR represent well-
characterized EPs that belong to the SMR family, which is constituted of four transmembrane-
containing transporters (91, 101). Smr from Staphylococcus aureus requires the ΔpH and ΔΨ 
for efficient transport of a wide range of drugs and other small compounds (102). 
Reconstitution experiments with both Smr and Emr confirm that these EPs require the PMF 
and operate through a drug/proton antiport mechanism (103). The RND proteins constitute the 
third family of broad substrate EPs that require the PMF for activity and are structurally more 
complex than SMR EPs, containing 12 transmembrane domains and various loop regions (104, 
105). Unlike the MFS family of EPs, these proteins are phylogenetically closely related, 
suggesting that they evolved from a single founding member (91). In addition to being 
autonomous transporters, the members of the RND family of proteins interact with other 
transport proteins in Gram-negative bacteria such as membrane fusion proteins (MFPs) and 
outer membrane factors (OMFs) to facilitate the transport of a variety of substrates (Figure 2.1) 
(105–107).  
The genome of M. tuberculosis retains multiple homologues of the major families of PMF-
dependent EPs described above and, in addition, encodes numerous ABC-type transporters or 
hypothetical proteins with homology to transporters (17, 108, 109). This complex multiplicity 
of EPs, detailed in Table 2.1, illustrates the ability of the tubercle bacillus to transport a variety 
of toxic compounds or antibiotics and has important implications for drug resistance in TB 
infection. The key feature of note is that many of these transport systems require either the 
PMF or ATP, thus linking their activity with metabolic flux through the ETC and the 
maintenance of an energized membrane.   




Table 2.1 Putative efflux pumps in M. tuberculosis. 







regulated in clinical 
isolates 
Differentially 
regulated by drugs 
References 
Rv0037c Probable conserved integral 
membrane protein 
MFS ATP  Yes  (110)  
Rv0194 Drugs-transport transmembrane 
ATP-binding protein  
ABC ATP    (17, 111)  
mmpS5 
(Rv0677c) 
Membrane protein mmpS5 RND PMF TET   (17, 112)  
Rv0849 Probable conserved integral 
membrane protein 
MFS PMF β-lactams   (113)  
Rv1218c Probable tetronasin-transport 
ATP-binding  
ABC ATP β-lactams   (113) 
Rv1250 Probable drug transport integral 
membrane protein 
MFS PMF  Yes  (110) 
Rv1258c Conserved membrane transport 
protein 
MFS PMF INH, RIF, EMB, OFL, 
β-lactams 







ABC ATP    (17, 118)  
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ABC ATP    (17, 118)  
Rv1410c Aminoglycosides/tetracycline-
transport integral membrane 
protein 
MFS PMF  Yes INH, RIF (110, 115)  
Rv1456c-
Rv1458c 
Integral membrane proteins ABC ATP  Yes (in drug 
resistant 
isolates) 
 (17, 119) 
Rv1463 
 




ATP    (17) 
Rv1634 
 
Drug efflux membrane protein MFS 
 
PMF  Yes  (17, 109, 110, 
120, 121)   
Rv1686c Probably conserved ATP-
binding protein 
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Rv1687c Probably conserved ATP-
binding protein  
ABC ATP  Yes  (110) 
Rv1747 
 






  (17, 118)  
Rv1877 
 
Conserved membrane protein MFS 
 
PMF TET, KAN, 
erythromycin 





ATP-binding protein  
ABC ATP   INH, RIF  (17, 115, 123, 
124)  
Rv2209 Probable conserved integral 
membrane protein 
?? ??   OFL (124) 




PMF TET, spectinomycin 
 








PMF   INH, EMB (17, 120, 124, 
126, 127)  
Rv2477c Probable macrolide-transport 
ATP-binding protein  
ABC ATP   OFL (124) 
Rv2686c Antibiotic-transport membrane 
leucine and alanine and valine 
rich protein  
ABC ATP CIP 
 




leucine and valine rich protein  
ABC ATP CIP 
 
  (17, 118, 128)  
Rv2688c Antibiotic-transport ATP-
binding protein  
ABC ATP CIP  STR (17, 118, 124, 
128)  
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Conserved membrane protein MFS 
 
PMF   STR (17, 120, 121, 
124) 
Rv3000 Possible conserved 
transmembrane protein 
ABC ATP  Yes  (110) 
Rv3239c 
 



















ATP TET, STR, EMB, RIF 
 
Yes   (17, 110, 118, 








ATP TET, STR, EMB 
 










ATP TET, STR, EMB 
 









PMF possibly INH 
 
 INH (17, 121, 124, 
132, 133)  
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Possible multidrug resistance 








Isoniazid inducible gene protein 
iniA 
membrane protein  INH, EMB 
 




Isoniazid inducible gene protein 
iniB 
membrane protein  INH 
 
  (17, 135, 136)  
iniC 
(Rv0343) 
Isoniazid inducible gene protein 
iniC 
membrane protein  INH 
 




transmembrane transport protein 
mmpL3 











transmembrane transport protein 
mmpL5 




transmembrane transport protein 
mmpL7 
RND PMF INH Yes  (17, 110, 128, 
137)  
Stellenbosch University  https://scholar.sun.ac.za







transmembrane transport protein 
mmpL11 
 
RND PMF    (17, 137)  
mmr 
(Rv3065) 






 INH, EMB (17, 109, 113, 





ABC ATP INH, RIF, EMB, CIP   (17, 117, 118, 
130, 138, 139)  
Transporter families were identified by literature searches (relevant cases are cited in the text) and from the genomic annotation/comparisons 
 (http://genolist.pasteur.fr/TubercuList/ and http://tuberculist.epfl.ch/) 
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Further associations between the PMF and drug efflux in mycobacteria have been made 
through various studies which demonstrated that dissipation of the PMF by treatment with 
efflux pump inhibitors (108, 114, 126, 140) can reverse low levels of resistance to TB drugs. 
Early work with 14C-labeled RIF suggests that this drug may be extruded from mycobacteria 
by the activity of PMF-dependent efflux pumps—a process that can be marginally reversed by 
the addition of reserpine, an EP inhibitor (141). In drug-resistant strains, exposure to efflux 
pump inhibitors such as verapamil, reserpine, Phe-Arg-β-naphthylamide (PAβN), carbonyl 
cyanide m-chlorophenylhydrazone (CCCP), and 2,4-dinitrophenol (DNP) restores 
susceptibility to anti-TB drugs such as RIF and ofloxacin (OFL) (129, 142, 143). Inclusion of 
verapamil in drug susceptibility assays results in a marked decrease in the MIC for bedaquiline 
and clofazimine (144). Knockout studies have further implicated efflux pumps such as 
Rv1218c, Rv3065, Rv0849, and Rv1258c as important mechanisms of resistance to various 
chemical classes of drug compounds in M. tuberculosis (145, 146). A recent study 
demonstrated increased expression of 15 EP-encoding genes, from various classes, in drug-
susceptible and drug-resistant strains compared to reference, laboratory grown strains (110). 
These data suggest that infection in the human host presumably drives expression of these 
genes to transport/detoxify noxious compounds during pathogenesis, with the concomitant 
benefit of drug extrusion. Similarly, the expression of 10 EP-encoding genes—Rv3065 (mmr), 
Rv2938 (drrC), Rv1819c (bacA—recently implicated in vitamin B12 acquisition [123]), 
Rv2209, Rv2459, Rv2477, Rv2688, Rv2846 (efpA), Rv2994, and Rv3728—is differentially 
induced during in vitro drug treatment of clinical isolates with standard TB drugs (124), as 
detailed further in Table 2.1, suggesting a complex induction pattern of these genes during 
short-course chemotherapy. While the regulatory mechanisms governing these gene expression 
changes have not been completely described, there is some evidence for transcriptional 
regulation of EPs. In this regard, it has been shown that WhiB7, a redox-sensitive 
transcriptional activator, plays an important role in mediating intrinsic drug resistance in 
mycobacteria, in some cases through direct regulation of EPs (147–149). Similarly, resistance 
to INH has been associated with the IniB-IniA-IniC efflux system (Table 2.1), which is 
regulated by the MtrAB two-component system (150), and the mmr-encoded EP is regulated 
by a TetR-type repressor (151). With respect to the evolution of drug resistance, transcriptional 
profiling of longitudinal isolates from drug-compliant patients, with MANU1, CAS, and 
Beijing spoligotypes, revealed upregulation of various EPs/multidrug resistance proteins, 
including Rv3065 (mmr), Rv2936 (drrA), Rv2397, Rv1686c, and Rv1687c, pointing to a role 
for these proteins in the evolution of drug resistance during treatment (122). Increased 




expression of genes encoding various efflux pumps upon exposure to RIF has been observed 
in M. tuberculosis which, in some cases, has been coupled with an increase in RIF and OFL 
tolerance. This phenomenon could be reversed by the addition of efflux pump inhibitors, 
highlighting the role of efflux in drug resistance (114–116, 129, 152). A similar result was 
observed during macrophage infection, where efflux pump activity was coupled to RIF and 
INH tolerance in M. tuberculosis (153). In RIF mono-resistant and susceptible M. tuberculosis 
isolates, initial low-level resistance to INH (reversible by the addition of efflux pump 
inhibitors) preceded the development of drug resistance-conferring mutations (126). Recently, 
it has been demonstrated that two EP-encoding genes, those encoding Rv2936 and Rv0783 
(Table 2.1), are associated with RIF resistance in RIF-mono-resistant clinical isolates. Over 
expression of these two genes, but not of that encoding Rv0933, resulted in increased RIF 
resistance in E. coli (130). Similarly, low-level efflux-induced azithromycin resistance in M. 
avium was followed by reversible high-level resistance, thought to be due to acquisition of 
mutations (140).  
These data suggest that the initial efflux activity allows antibiotic tolerance in mycobacteria, 
enabling resistance-causing mutations to arise and/or be selected for. In this context, the 
production of ATP via the F1F0-ATP synthase would be essential for the function of these 
systems. Since efflux pumps seem to play an important role in contributing to drug tolerance, 
which may then lead to drug resistance, the driving energetic force behind these pumps 
represents an additional point of vulnerability with respect to targeted drug design in 
mycobacteria. Studies using PMF and ATP synthase inhibitors have demonstrated the role of 
the PMF and ATP in INH efflux in M. smegmatis (135). Although efflux has been studied in 
M. tuberculosis, the role of the driving force of these pumps in drug resistance remains poorly 
investigated. Direct coupling of PMF and ATP to drug efflux—and consequent drug 
resistance—has been investigated in E. coli, B. subtilis, L. lactis, Streptococcus pneumoniae, 
and a host of other organisms (reviewed in references 91, 97, 104, 105, 154, 155, 156, 157, and 
158). Considering the success in targeting the ETC in TB drug development, together with the 
demonstrated importance of efflux as an active process contributing to drug resistance, the role 
of energy metabolism in drug resistance and inherent susceptibility in M. tuberculosis merits 
further investigation. The recent demonstration that iron-sulfur (Fe-S) cluster biogenesis is 
related to intrinsic susceptibility of bacteria to aminoglycosides due to the use of an alternate 
pathway for Fe-S biogenesis, which results in perturbations in the ETC, leading to reduced 
PMF and altered drug uptake (159), is consistent with this. Little is known about the energy 




requirements of mycobacteria during infection, although it has been demonstrated that ATP 
levels are important for survival in actively replicating as well as nonreplicating mycobacteria, 
demonstrating the importance of maintaining ATP levels under conditions of growth and 
survival (20, 55). These ATP levels and associated PMF are essential for M. tuberculosis to 
extrude drugs via PMF-dependent EPs.  
The presence of numerous potential regulators involved in the control of cellular ATP levels 
suggests that there may be different mechanisms involved in the regulation of ATP synthesis. 
It has been demonstrated that, although ATP levels drop significantly during the shift down to 
a nonreplicating state, the decreased levels of cellular ATP are essential for viability since 
treatment with bedaquiline resulted in a loss of viability. M. smegmatis displays up regulation 
of F1F0-ATP synthase in response to antibiotic stress. For example, an increase in F1F0-ATP 
synthase abundance was observed upon the exposure of M. smegmatis to ethambutol (EMB). 
Furthermore, among the other proteins up regulated in response to EMB, 23% were related to 
energy metabolism (160). Similarly, treatment with β-lactam antibiotics resulted in increased 
expression of F1F0-ATP synthase in M. tuberculosis (51). These data suggest that antibiotic 
treatment may inflict physiological stresses on bacteria that impose a requirement for greater 
energy production. In the case of β-lactam antibiotics, it is unclear whether their effect on the 
cell wall results in a perturbation of the PMF which is compensated for by an up-regulation of 
the genes encoding the ATP synthase. There have been no extensive studies showing the 
response of pathways involved in energy metabolism to anti-TB treatments such as RIF; this 
could provide novel insight into cellular responses or adaptations occurring within the cell 
leading to drug resistance or identification of targets for drug development.  
Concluding remarks 
The ETC and associated PMF are essential components for energy production through the 
generation of ATP, which is required for metabolic processes within the cell. The ETC has 
gained recent prominence in TB drug development through the discovery of numerous 
compounds that target this pathway such as bedaquiline and Q203. However, in addition to the 
obvious effects of inhibiting the ETC, a secondary effect of targeting this pathway would be a 
reduction in the activity of the various PMF/ATP-dependent EPs present in M. tuberculosis. 
These effects may accelerate cell death through higher intracellular concentrations of drugs and 
reduced extrusion of toxic metabolites, with an added benefit of reducing transient drug 
tolerance and consequent drug resistance. Various studies now point to potentially positive 




therapeutic effects of using EP inhibitors such as verapamil to increase the potency of drugs 
and limit the acquisition of drug resistance. Energy metabolism, including the regulation 
thereof, represents an ideal component of metabolism to mine for new drug targets.  
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3.1. Strain selection 
Stellenbosch University, Department of Biomedical Sciences has an extensive Mycobacterium 
tuberculosis strain culture bank containing approximately 20 000 isolates, collected from 2001 
to present. These isolates represent all culturable drug resistant isolates from the Western Cape 
region of South Africa. A large proportion of isolates have been genotyped by spoligotyping, 
representing numerous clades and lineages. Approximately 70% of the drug resistant epidemic 
in the Western Cape is driven by 4 strain families: Beijing/W-like (28%), Low Copy Clade 
(LCC) (26%), F11 (12%) and F28 (5%) (1). Resistance profiles range from mono-resistant to 
totally drug resistant (TDR) (in the sense that these isolates are resistant to all available drugs 
used to treat TB in South Africa); a subset of which reflect intra-patient evolution (in vivo 
evolution). For the purpose of this study the M. tuberculosis strain culture bank was 
interrogated to select a sample set where in vivo evolution of drug resistance was observed.  
Briefly, patients with more than one clinical sample present in the strain culture bank were 
selected; multiple samples per patient were analysed to determine if M. tuberculosis had 
acquired additional drug resistance during the course of infection i.e. an initial sample was 
mono-resistant while a follow up sample has gained resistance to an additional anti-TB drug. 
The final sample set selected for this study samples consisted of isolates that demonstrate intra-
patient evolution i.e. samples from individual patients where an initial sample shows to be 
rifampicin mono-resistant, and a follow-up sample multi-drug resistant (MDR). A total number 
of 66 isolates originating from 31 patients were selected for strain characterization (Appendix 
2, Table A2.1). 
Isolates shown to demonstrate intra-patient evolution of drug resistance from rifampicin mono-
resistant to MDR were used to investigate the role of efflux pumps in the evolution of drug 
resistance. These isolates were characterised in Chapter 4. In addition, a separate panel of well 
characterised rifampicin mono-resistant M. tuberculosis clinical isolates were selected from the 
culture bank for this study (Table 3.1). These isolates represent numerous genetic backgrounds 
and rpoB mutations causing rifampicin resistance.  
A set of in vitro generated rifampicin resistant M. tuberculosis mutants as well as their pan 
susceptible progenitor were also selected for analysis (Table 3.1). The in vitro M. tuberculosis 
rifampicin resistant mutants were previously generated in our department by Dr M de Vos, to 
provide a sample set with a “clean” genetic background to further investigate rifampicin 




resistance mechanisms in M. tuberculosis. The in vitro mutants selected for this study had been 
fully characterized and analysed by whole genome sequencing (WGS) analysis (Table 3.2).  





















R966 Beijing His526Tyr 
Rifampicin mono-
resistant 
R5608 EAI Ser531Leu 
Rifampicin mono-
resistant 












 K636 Beijing - Pan-susceptible 
K.531 Beijing Ser531Leu 
Rifampicin mono-
resistant 
K.526 Beijing His526Tyr 
Rifampicin mono-
resistant 
*Amino acid change according to the Escherichia coli rpoB gene sequence 
 
Table 3.2 Novel genetic variants unique to M. tuberculosis rifampicin resistant in vitro generated 
mutants relative to the pan-susceptible progenitor. 
 Locus Gene Amino 
acid 
change 
Gene description Functional group 
k.531 Rv0667 rpoB Ser531Leu
* 
DNA-directed RNA 
polymerase beta chain 
Information 
pathways 




k.526 Rv0667 rpoB His526Tyr* DNA-directed RNA 
polymerase beta chain 
Information 
pathways 
*Amino acid change according to the Escherichia coli rpoB gene sequence 
3.2. Mycobacterial strain culture 
The selected clinical M. tuberculosis isolates are all preserved as coated glass bead stocks at -
80°C within the Department of Biomedical Sciences. BACTEC™ Mycobacterial Growth 




Indicator tubes (MGIT™ 960) were supplemented with OADC and inoculated with a single 
glass bead. Each inoculated MGIT was incubated in the BACTECTM MGITTM 960 instrument 
at 37°C. Following an indication of growth positivity, each MGIT was incubated at 37°C for 
an additional 5 days to allow for optimal mycobacterial growth units. A volume of 500μl of 
positive culture was then used to inoculate a starter culture in 10ml of 7H9 Middlebrook 
medium (Becton, Dickinson Microbiology system, Sparks, USA) (see appendix 1), 
supplemented with 10% albumin-dextrose-catalase (ADC), 0.2% (v/v) glycerol (Merck 
Laboratories, Saarchem, Gauteng, SA) and 0.1% Tween80 (Becton, Microbiology systems, 
Sparks, USA). Cultures were then grown in filtered screw cap tissue culture flasks (Greiner 
Bio-one, Maybachstreet, Germany) without shaking at 37°C until an optical density (OD600) of 
0.6-0.8 was reached. Ziehl-Neelsen (ZN) staining and plating cultures onto blood agar plates 
were done to assess contamination. An aliquot of M. tuberculosis culture was boiled and stored 
separately for subsequent PCR screening. An additional aliquot was plated on 7H10 media 
supplemented with OADC for subsequent DNA extraction. Glass bead and glycerol stocks (1:1 
v/v, 500μl culture and 500μl 50% glycerol) were prepared and stored at -80°C.  
3.3. Strain characterization 
The 66 prospective M. tuberculosis isolates demonstrating in vivo evolution of drug resistance 
were screened for genotypic drug resistance using targeted PCR and Sanger sequencing of 
known drug resistance causing genes. In addition, these isolates were subjected to 
spoligotyping to determine strain family/genetic background. A refined list of isolates was 
subjected to phenotypic drug susceptibility testing for rifampicin and isoniazid to confirm the 
observed genotypes.  
3.3.1. Targeted PCR and Sanger sequencing 
PCR amplification of the known drug resistance associated genes (Table 3.3) was done by 
adding a 2µl of the boiled culture to a PCR reaction mixtures containing 1X Q buffer, 1X PCR 
buffer, 2mM MgCl2, 0.4mM dNTPs, 50μM of each drug resistance associated gene primers 
(Table 3.3) and 1.25U Hot Star Taq polymerase (Qiagen, San Diego, CA, USA). Amplification 
was done under the following conditions: 95°C for 15 minutes; 40 cycles of 95°C for 30s, 
primer Tm for 30s (Table 3.1), and 72°C for 2 minutes; one cycle of 72°C for 5 minutes. 
Amplification for the rpoB gene was performed using a touchdown PCR. Reaction conditions 
are as follows: 95°C for 15 minutes, 2 cycles of 94°C for 1 minute, 72°C for 1 minute and 72°C 




for 1 minute, 2 cycles of 94°C for 1 minute, 71°C for 1 minute and 72°C for 1 minute, 2 cycles 
of 94°C for 1 minute, 70°C for 1 minute and 72°C for 1 minute and 40 cycles of 94°C for 1 
minute, 69°C for 1 minute and 72°C for 1 minute, with a final extension step of 72°C for 10 
minutes. 
PCR products were electrophoretically fractionated in a 2% agarose gel (100 volts, 1 hour) and 
visualised after ethidium bromide staining. Subsequently, the amplified products were 
sequenced (ABI PRISM DNA sequencer Model 377, Perkin Elmer) using the gene specific 
primers (Table 3.3). Sequences were aligned to the genome sequence of M. tuberculosis H37Rv 
(www.genolist/tuberculist/) using BioEdit Sequence Alignment Editor software (Ibis 
Biosciences, Carlsbad, CA, USA) and Basic Local Alignment Search Tool (BLAST) analysis 
(www.ncbi.nim.nih.gov/BLAST/). 
Table 3.3 Primer sequences used to amplify drug resistance associated genes in M. tuberculosis. 






Forward TGGTCCGCTTGCACGAGGGTCAGA 78 
437 




























M. tuberculosis isolates were genotyped according to the internationally standardized method 
of spoligotyping as previously described (2).  




3.3.3. Drug susceptibility testing 
This method was adapted and modified from Siddiqi et al., 2012 (3). A BACTEC™ MGIT™ 
960 vial was supplemented with 0.8ml OADC, and subsequently inoculated with 0.1ml Freezer 
stock of the respective M. tuberculosis clinical isolates. The MGIT was incubated in the 
BACTEC™ MGIT™ 960 instrument at 37°C. Following indication of growth positivity, 0.1ml 
of the MGIT positive culture was sub-cultured into a fresh MGIT vial, supplemented with 
0.8ml OADC. Once this vial was indicated positive growth, drug susceptibility tests (DSTs) 
were set up for RIF and INH. Briefly, 0.8ml OADC was added to each MGIT vial. For the 
rifampicin DST 0.1ml of rifampicin was added to a final concentration of 1μg/ml (critical 
concentration as defined by the WHO). For isoniazid two DSTs were set up per sample, where 
0.1ml of isoniazid was added to a final concentration of 0.1 and 1μg/ml isoniazid to 
differentiate between low and high level INH resistance, respectively. The prepared MGIT 
vials were inoculated with 0.5ml of the positive MGIT culture. In addition 0.5ml of a 1:100 
dilution of the MGIT positive culture was inoculated into an OADC supplemented MGIT vial 
in the absence of antibiotic as a growth control. Inoculated MGIT vials were incubated in the 
BACTEC™ MGIT™ 960 instrument at 37°C; the growth unit (GU) was monitored until the 
growth control reached a GU of 400. An isolate was defined as resistant if the experiment tube 
(containing drug) had a GU of 100 or more when the GU of the growth control reached 400. 
Conversely, an isolate was scored as sensitive if no growth was observed i.e. no change in GU, 
or the GU had not reached 100 when the growth control had reached a GU of 400.   
3.4. DNA extraction 
DNA was extracted according to standard protocols (4). Briefly, M. tuberculosis isolates 
cultured on 7H10 agar supplemented with OADC were heat killed at 80°C for one hour before 
being scraped into a 50ml tube containing glass beads and extraction buffer (Appendix 1), and 
vigorously vortexed. The bacilli were then treated by incubation at 37°C for 2 hours in the 
presence of 100mg/ml of lysozyme (Roche, Germany) and 50mg RNAse A (Roche Germany). 
The bacilli were subsequently digested with 1.5mg proteinase K (Roche, Germany) in the 
presence of 1X proteinase K buffer (Appendix 1) at 42°C for 16 hours. To remove pretentious 
material an equal volume of phenol:chloroform;isoamyl alcohol (25:24:1) was added to each 
digest and inverted every 30 minutes, for 2 hours. Phase separation was achieved by 
centrifugation at 3000rpm for 20 minutes at room temperature. Thereafter the aqueous phase 
was transferred to a clean 50ml tube containing an equal volume of chloroform:isoamyl alcohol 




(24:1). Following inversion the mixture was separated by centrifugation at 3000rpm for 20 
minutes at room temperature. DNA from the resultant aqueous phase was precipitated 
following the addition of 1/10 volume of 3M sodium acetate (pH5.2) and an equal volume of 
isopropanol. The precipitated DNA was collected on a glass rod, washed in 70% ethanol for 
10 minutes and left to air dry at room temperature before being dissolved in TE (Appendix 1).  
3.5. RFLP DNA fingerprinting 
DNA was subjected IS6110 RFLP fingerprinting according to the internationally standard 
protocol (4).  
3.6. Illumina sequencing 
WGS of M. tuberculosis isolates demonstrating in vivo evolution of drug resistance was done 
at the Next Generation Sequencing Facility (NGFS) at the University of the Western Cape and 
at the Centre for Proteomic and Genomic Research (CPGR), Cape Town, South Africa. DNA 
was sequenced on the IlluminaMiSeq platform using the MiSeq Reagent kit v3 (Illumina, CA, 
USA) generating paired end reads. 
3.7. Bioinformatic analyses 
Bioinformatic analysis of all Illumina sequencing data was done in collaboration with Dr M de 
Vos, Dr R van der Merwe and Dr A Dippenaar in the Department of Biomedical Sciences, 
Stellenbosch University. All Illumina raw sequencing data were in the fastq file format, which 
was used as a starting point for subsequent bioinformatic analysis. The approach followed for 
the analysis of each isolate is depicted in Figure 3.1. The raw sequencing reads were run 
through an automated pipeline developed by Dr R van der Merwe (manuscript in preparation). 
The steps involved in this pipeline are described briefly below. 
3.7.1. Quality assessment 
Raw sequencing reads for each M. tuberculosis isolate were evaluated using FastQC software 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). This software validates the raw 
sequencing reads and generates quality scores based on the quality of the sequences, the content 
of the sequences as well as the level of duplication which occurred during sequencing. In 
addition the following data is generated for each isolate: read length, number of reads processed 
and the GC content of the reads. 




3.7.2. Alignment and mapping to M. tuberculosis H37Rv reference genome 
Trimmomatic version 0.32 (5) was used to identify and remove adapter sequences used for 
Illumina sequencing. In addition, Trimmomatic-0.32 removes low quality sequences by 
utilising a sliding window to assess the base quality across each read. It has been shown that 
using Trimmomatic-0.32 for pre-processing of Illumina reads improves the quality of the 
down-stream analyses steps (5).  
Trimmed Illumina reads were subsequently aligned to the M. tuberculosis H37Rv reference 
genome using 3 aligners, namely: Novoalignv3-02-04 
(http://www.novocraft.com/main/index.php), Burrows-Wheeler Alignment tool (BWA) v0.7.8 
(6) and SMALT v0.7.5 (https://www.sanger.ac.uk/resources/software/smalt/#t_1). Utilisation 
of three independent aligners, each one using a different algorithm, minimises the identification 
of false positive variants being called due to mis-alignment. Each aligner used in this study 
required the reference genome to be indexed. The M. tuberculosis H37Rv genome used for this 
study was accessed from http://www.ncbi.nlm.nih.gov/nuccore/AL123456.3.  
  



















Figure 3.1 Schematic representation of the bioinformatics pipeline used in this study to assess Illumina 
sequencing data. 
3.7.2.1. Novoalign 
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BWA utilises Burrows-Wheeler Transform (BWT) to align short reads to a reference genome.  
3.7.2.3. SMALT 
SMALT utilises a banded Smith-Waterman algorithm to aligned Illumina reads to an indexed 
reference genome.  
Each aligner generates an output file in a Sequence Alignment/Map format (SAM). Each SAM 
file generated by the different aligners is subsequently validated using Picard version 1.107 
(http://picard.sourceforge.net). Sam tools was then used to convert the SAM files generated to 
binary format (BAM file), before sorting and indexing the resultant BAM file. 
3.7.2.4. Conversion, sorting and realignment of BAM files 
Following this conversion and sorting of the BAM files the Genome Analysis Toolkit (GatK) 
version 3.1-1 was used to realign misaligned reads by insertions and deletions (InDels) within 
the sequenced genome. Picard version 1.107 was subsequently used again to sort and index 
these realigned BAM files. The “Mark Duplicates” function of Picard version 1.107 was used 
to find and remove and PCR duplicates which may have been generated during the sequencing 
reaction. Once all PCR duplicates were removed SAM tools was used to index this BAM file 
again.  
3.7.2.5. Variant calling and annotation 
The resultant BAM files were used to identify two types of variants, namely single nucleotide 
polymorphisms (SNPs) and InDels. The UnifiedGenotyper tool of GatK was used to call 
variants with a quality value above 50. Any variants with a quality score between 10 and 50 
were still included for further analysis.  
Three separate lists of variants were generated from this analysis, one for each aligner used. 
Polymorphisms which were present in all three lists were extracted using in-house python 
scripts (Dr R van der Merwe, manuscript in preparation) and considered to be high confidence 
polymorphisms (Figure 3.1). These variants were annotated using Tuberculist data 
(http://genolist.pasteur.fr/TubercuList/) and in-house python scripts. 




3.7.2.6. Phylogenetic analysis 
A molecular phylogenetic analysis was done to confirm that the M. tuberculosis isolates from 
the same patient cluster together in the correct lineages. The evolutionary history was inferred 
by using the Maximum Likelihood method based on the General Time Reversible model (7). 
The bootstrap consensus tree inferred from 1000 replicates is taken to represent the 
evolutionary history of the taxa analysed (8). Branches corresponding to partitions reproduced 
in less than 50% bootstrap replicates are collapsed. Initial tree(s) for the heuristic search were 
obtained automatically by applying Neighbor-Join and BioNJ algorithms to a matrix of pair-
wise distances estimated using the Maximum Composite Likelihood (MCL) approach, and then 
selecting the topology with superior log likelihood value. The analysis involved 24 nucleotide 
sequences. All positions containing gaps and missing data were eliminated. There were a total 
of 20961 positions in the final dataset. Evolutionary analyses were conducted in MEGA5 (9). 
3.7.3. Identification of polymorphisms unique to each rifampicin mono-resistant and 
MDR isolate 
To identify polymorphisms associated with the evolution of drug resistance i.e. unique to each 
rifampicin mono-resistant and MDR isolate the lists of high confidence variants generated in 
section 3.7.2 were compared and a list of unique polymorphisms were generated for each 
isolate using in-house python scripts. In addition, a list of common polymorphisms shared 
between the rifampicin mono-resistant and MDR isolate was generated for each sample set.  
3.7.4. Validation of polymorphisms 
High confidence polymorphisms were manually inspected using Genomeview 
(www.genomeview.org) to ensure that a polymorphism considered unique to one isolate was 
indeed not present in the paired isolate. Polymorphisms were subsequently filtered based on 
their quality values (a quality score of 50 was used as a cut-off). A final list of polymorphisms 
for each isolate was validated using targeted PCR and Sanger sequencing. Briefly, an aliquot 
of genome DNA was added to the following reaction mix containing: 1XQ buffer, 1X PCR 
buffer, 2mM MgCl2, 0.4mM dNTPs, 50μM of each primer (Table 3.4) and 1.25U Hot Star Taq 
polymerase (Qiagen, San Diego, CA, USA). Amplification was done under the following 
conditions: 95°C for 15 minutes; 40 cycles of 95°C for 30s, primer Tm for 30s (Table 3.4), and 
72°C for 2 minutes; one cycle of 72°C for 5 minutes.  




PCR products were electrophoretically fractionated in a 2% agarose gel (100 volts, 1 hour) and 
visualised after ethidium bromide staining. Subsequently, the amplified products were 
sequenced (ABI PRISM DNA sequencer Model 377, Perkin Elmer) using the gene specific 
primers (Table 3.4). Sequences were aligned to the genome sequence of M. tuberculosis H37Rv 
(www.genolist/tuberculist/) using BioEdit Sequence Alignment Editor software (Ibis 
Biosciences, Carlsbad, CA, USA) and Basic Local Alignment Search Tool (BLAST) analysis 
(www.ncbi.nim.nih.gov/BLAST/). 
Table 3.4 Primer sequences used to validate polymorphisms identified by whole genome sequencing 
analysis. 
















































































Rv3391 CGTGCCGGTCGACTATGT 60 235 














































































3.8. Minimum Inhibitory Concentration (MIC) determination 
This technique was adapted and modified from (10). Briefly, M. tuberculosis isolates were 
cultured in 7H9 supplemented with OADC to an OD600 of 0.2-0.3 and thereafter a 1:100 
dilution was prepared in 7H9 media. MIC plates were set up in 96-well round-bottom micro 
titre plates. A volume of 50μl 7H9 supplemented with OADC was added to each well in rows 
2 to 12. No media was added to row 1.  
In row 1, 100μl of media was added to the first well to serve as a control. An additional control 
of 10% DMSO (diluted in media) was added to the second. Rifampicin at a concentration 4 x 
greater than the highest desired rifampicin concentration was added to the remaining 6 wells 




of row 1 (diluted in 10% DMSO in media). From row 1 through to row 12 a 1:2 dilution series 
was carried out, subsequently diluting rifampicin in each new row. A volume of 50μl of the 
1:100 dilution of M. tuberculosis was added to every well in rows 2 to 12. The micro titre plates 
were then sealed and incubated at 37°C for 7 to 14 days. Plates were subsequently scored for 
growth or no growth to determine the rifampicin MIC. A range of concentration from 20 to 
250μg/ml rifampicin was tested.  
The MIC can be defined as the lowest anti-TB drug concentration where there was no visible 
M. tuberculosis growth (11). 
3.9. Determination of the role of efflux pump in drug resistance in M. tuberculosis 
(inhibitor experiment) 
3.9.1. Effect of efflux pump inhibitor verapamil on the growth of M. tuberculosis to 
rifampicin 
Inhibitor experiments were carried out in the BACTEC™ MGIT™ 960 instrument as described 
above, and were adapted from Siddiqi et al., 2012 (3). The following vials were set up for each 
M. tuberculosis isolate: a growth control (MGIT inoculated with a 1:100 dilution of the 
culture), an positive growth control (MGIT inoculated with undiluted culture), rifampicin 
control (MGIT inoculated with undiluted culture and containing a final concentration of 
10μg/ml RIF), verapamil control (MGIT inoculated with undiluted culture and containing a 
final concentration of 50μg/ml verapamil) and an experimental vial (MGIT inoculated with 
undiluted culture and containing a final concentration of 10μg/ml rifampicin and 50μg/ml 
verapamil). Inoculated MGIT vials were incubated in the BACTEC MGITTM 960 instrument 
at 37°C; the GUs were monitored until the growth control reached a GU of 400.  
The percentage of susceptibility restored by efflux pump inhibitor verapamil was calculated at 
previously described (12), at the point in growth were the growth control reached a GU of 400.  
((GUDRUG – GUEPI+DRUG) – (GUCONTROL-GUEPI)) 
                            GUDRUG 
 
Where: GUDRUG = growth units in the presence of 10μg/ml rifampicin  
GUEPI = growth units in the presence of 50μg/ml verapamil  




GUEPI+DRUG= growth units in the presence of 10μg/ml rifampicin and 50μg/ml and verapamil 
GUCONTROL= growth unit in the absence of any drug (undiluted growth control) 
3.9.2. Effect of efflux pump inhibitor verapamil on the level of rifampicin resistance of M. 
tuberculosis  
The MIC values for rifampicin were determined in the presence and absence of efflux pump 
inhibitor verapamil in the BACTEC™ MGIT™ 960 instrument as described above, and 
adapted from Siddiqi et al., 2012 (3). The following vials were set up for each M. tuberculosis 
isolate: MGIT inoculated with a 1:100 dilution of the culture), a positive growth control (MGIT 
inoculated with undiluted culture), and vials for MIC determination. Each concentration used 
had 2 MGIT vials, one containing 50μg/ml verapamil, and one with no verapamil present.  
For rifampicin concentrations a ¼ and ½ MIC were used (based on the MIC determined for 
each isolate in section 3.8). For each rifampicin concentration 2 vials were used, one containing 
50μg/ml verapamil, and one with no verapamil present. Inoculated MGIT vials were incubated 
in the BACTEC MGIT 960 instrument at 37°C; the MIC was determined when the 1:100 
growth control reached a GU of 400. Experiments were monitored for a further 7 days.  
3.10. Gene expression analysis 
M. tuberculosis was inoculated into 5ml of 7H9 supplemented with ADC as an initial starter 
culture. At an OD600 of 0.8 M. tuberculosis was sub-cultured into 50ml 7H9 supplemented with 
ADC for the growth curve cultures. OD600 readings were measured over a period of 28 days to 
generate growth curves for each M. tuberculosis isolate in order to determine mid-log phase. 
Once the mid-log phase was determined, each M. tuberculosis isolate was cultured in 7H9 
supplemented with ADC. Two cultures were set up for each isolate. At mid-log on culture of 
M. tuberculosis was exposed to rifampicin concentration equivalent to ¼ MIC (determined in 
section 3.8) for a period of 24 hours before RNA was extracted. The second culture served as 
an unexposed control culture.  
3.10.1. RNA extraction 
M. tuberculosis RNA was isolated using the FastRNA® Blue kit (MP Biomedicals LLC, CA, 
USA). This technique was adapted and modified from the manufacturer extraction protocol. 
Briefly, 5 culture volumes of GITC solution (Appendix 2) was added to each M. tuberculosis 




culture before centrifugation at 4000rpm for 10 minutes at 4°C. Pellets were resuspended in 
1ml of RNApro solution before being transferred to a 2ml screw-cap containing Lysing Matrix 
B. Culture suspensions were subsequently homogenised in a FastPrep®-24 Instrument (MP 
Biomedicals LLC, CA, USA) using 4 runs of 25 seconds at a setting of 6.5W. Samples were 
cooled on ice for 1 minute between each run. Following decontamination the lysates were 
removed from the BSL-3 laboratory and centrifuged at 12 000 rpm for 10 minutes at 4°C. The 
supernatant was transferred to 300μl of chloroform (Sigma-Aldrich, St Louis, Germany), 
vortexed and incubated for 5 minutes at room temperature. The RNA containing aqueous phase 
was separated by centrifugation at 12 000 rpm for 10 minutes at 4°C, and transferred to a new 
RNAse free Eppendorf tube containing 500μl RNAse free absolute ethanol (Sigma-Aldrich, St 
Louis, Germany) (cooled to -20°C). Samples were inverted to allow for mixing to occur before 
incubation at -20°C for 1 hour. Nucleic acids were subsequently pelleted by centrifugation at 
12 000 rpm for 20 minutes at 4°C before being washed with 500μl RNAse free 75% ethanol 
(Sigma-Aldrich, St Louis, Germany) (cooled to -20°C). Following the wash step the 
supernatant was discarded and the nucleic acid pellet left to air dry for 5 minutes. Pellets were 
resuspended in a total volume of 50μl RNAse free water and stored at -80°C until further use.  
3.10.2. DNAse treatment 
RNA samples were treated with RNAse-free DNAse to remove any residual genomic DNA 
(gDNA). A volume of 10μl of RNA was added to the following reaction: 10μL of DEPC-
treated H2O, 4μL of DNAse Buffer and 4μL of RQ1 DNAse (Promega, WI, USA). The DNAse 
treatment reaction mixture was incubated at 37°C for 30 minutes before RNAse-free water was 
added to the reaction to a total volume of 200μl. An equal volume of cooled 
phenol:chlorophorm (4:1, v/v) (Sigma-Aldrich, St Louis, Germany) was added before mixing 
by vortexing and incubation on ice for 10 minutes. Samples were subsequently centrifuged at 
12 000rpm for 10 minutes at room temperature to allow for phase separation. The upper 
aqueous phase was collected and added to 0.1 volumes of RNAse-free sodium acetate (pH 5.2) 
(Sigma-Aldrich, St Louis, Germany) and 2.5 volumes cooled absolute ethanol. Following 
mixing by vortexing, samples were incubated overnight at 4°C. DNA-free RNA was pelleted 
by centrifuged at 12,000 rpm for 30 minutes at 4°C and the resulting pellet was washed with 
500μL of cooled 75% ethanol. The 75% ethanol was aspirated and the RNA pellet was left to 
air-dry for 10 minutes before resuspending in a total volume of 13μl water. 
 




3.10.3. Assessment of RNA 
An aliquot of each RNA sample was removed for quality assessment. A volume of 1μl DNAse-
treated RNA was added to the following PCR reaction mixture to assess gDNA contamination: 
1X Q buffer, 1X PCR buffer, 2mM MgCl2, 0.4mM dNTPs, 50μM of each forward and reverse 
gyrA primer (Table 3.1) and 1.25U Hot Star Taq polymerase (Qiagen, San Diego, CA, USA). 
Amplification was performed under the following conditions: 95°C for 15 minutes; 40 cycles 
of 95°C for 30s, primer 62°C for 30s, and 72°C for 2 minutes; one cycle of 72°C for 5 minutes. 
M. tuberculosis genomic DNA was added to a reaction mix to serve as a positive PCR control. 
PCR products were electrophoretically fractionated in 2% agarose gel (100 volts, 1 hour) and 
visualised after ethidium bromide staining.  
An aliquot of DNA-free RNA was sent to the Stellenbosch University Central Analytical 
Facility (CAF) for Bioanalyser analysis to determine the integrity and concentration of RNA. 
Bioanalyser analysis generates an RNA Integrity Number (RIN) score for evaluation of RNA 
integrity. A value of 10 indicates completely intact RNA, while a value of 5 indicates partial 
degradation. RNA samples with a RIN score greater than 7 were used for further analysis.  
3.10.4. cDNA synthesis 
The QuantiTect Reverse Transcriptase Kit (Qiagen, San Diego, CA, USA) was used to 
synthesise cDNA from purified RNA according to manufacturer’s instructions. An amount of 
0.5μg RNA was added to the following reaction mix to eliminate any residual gDNA: 2μl 
gDNA buffer and RNAse-free water (to a final volume of 14μl). The gDNA wipeout reaction 
was incubated at 42°C for 2 minutes. Quantiscript RT buffer (1x), RT Primer mix (an optimised 
blend of oligo-dTs and random primers) and 1μl Reverse transcriptase. The reverse 
transcriptase mix was incubated at 42°C for 15 minutes, followed by incubation at 95°C for 3 
minutes to inactivate the reverse transcriptase. A no Reverse transcriptase control was included 
for each sample i.e. a cDNA synthesis reaction was set up without the Reverse transcriptase 
enzyme. 
3.10.5. Primer design for Quantitative Real Time PCR 
Primers were designed to investigate the expression of an array of efflux pumps and energy 
metabolism genes in M. tuberculosis (Table 3.5). To investigate the response of energy 




metabolism genes to rifampicin exposure one gene encoding each component of the electron 
transport chain was selected. To investigate the role of efflux pumps in drug resistance as well 
as in response to rifampicin exposure, numerous ABC transporter and MFS pumps were 
selected as well as one RND class pump.  
Table 3.5 Primer sequences used to amplify cDNA for quantitative real time PCR analysis. 











































































































3.10.6. Quantitative Real Time PCR 
The iScriptTM Reverse Transcriptase Supermix was used to set up all Quantitative Real Time 
PCR (RT-qPCR) reactions as per manufacturer’s instructions (Bio-rad Laboratories, CA, 
United States). Briefly 1μl of a 1:10 dilution of cDNA was added to 5μl SYBR Green mix, 
10μM of each forward and reverse primer and water was added to a final volume of 10μl. A no 
template control was added to assess contamination. In addition, a no reverse transcription 
control was included. RT-qPCR was performed using the CFX96 Touch™ Real-Time PCR 
Detection System (Bio-rad Laboratories, CA, United States). The following reaction conditions 
were used: 95°C for 30 seconds, 40 cycles of 95°C for 5 seconds, 62°C for 30 seconds followed 
by 65°C for 5 minutes.  
Each RT-qPCR experiment was done on triplicate biological samples that were each assayed 
in duplicate. 
3.10.7. Statistical analysis 
16S rRNA and sigA were included as housekeeping/reference genes for each RT-qPCR 
reaction. The level of gene expression of each individual gene was quantified by the delta-delta 
Ct calculation in which the relative abundance of the target gene was normalized relative to the 
levels of the housekeeping genes. Data analyses were done according to the delta-delta CT 
equation R=2 -(LCT sample -LCT control). Only experiments with a standard deviation of <0.5 
were included for analysis. Significant fold changes were identified based on The Relative 
Expression Software Tool -384 (REST-384©) that assigns significance with a significance 
level of 5% (13).  
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Evolution of drug resistance in Mycobacterium tuberculosis  





South Africa is ranked by the World Health Organisation as having one of the highest 
incidences of Tuberculosis (TB) globally. Control of this disease is threatened by the 
emergence of drug resistance. Multi-drug resistant (MDR) cases are classified as infection with 
Mycobacterium tuberculosis strains that are resistant to two of the first-line anti-TB drugs: 
isoniazid and rifampicin, while pre-extensively drug resistance (pre-XDR) is defined as MDR 
infection with additional resistance to a fluoroquinolone or to a second line injectable 
(kanamycin, amikacin or capreomycin), but not both. XDR is classified as infection with MDR 
with additional resistance to both a fluoroquinolone and a second line injectable (1, 2).  
Conventionally, drug resistance in M. tuberculosis has been associated with mutations in single 
target genes (1, 3). For example, a mutation in the rpoB gene causes rifampicin resistance. 
However, an increasing body of evidence suggests that additional mechanisms may be involved 
in the emergence and subsequence adaptation of M. tuberculosis phenotype prior to or 
following the evolution of drug resistance through a fixed mutation in a defined target gene. It 
has been shown that the activation of efflux may be the initial gateway mechanism enabling 
subsequent acquisition of resistance, but not necessarily be the sole cause of clinical resistance 
(4). Despite the role of efflux (discussed in Chapter 5), other mechanisms contributing to 
resistance as well as the physiological consequence of mutations has not been thoroughly 
investigated. 
More recently, whole genome sequencing (WGS) has been applied to investigate the evolution 
of drug resistance based on the hypothesis that additional mutational events may precede or 
occur concurrently with known resistance conferring mutations (4). A well-known example of 
such a phenomenon is the observation of compensatory mutations in M. tuberculosis (5, 6). 
Numerous studies have suggested that the development of drug resistance causing mutations 
may incur a fitness cost in M. tuberculosis (7–9). However, in vitro culture and epidemiological 
studies have demonstrated that drug resistant M. tuberculosis is able to compensate for the 
fitness cost associated with the accumulation of drug resistance conferring mutations (7, 8). 
The mechanisms responsible for ameliorating fitness cost remain largely unknown. Secondary 
mutations in rpoA and rpoC have been associated with rifampicin resistance, suggesting that 
these mutations may play a compensatory role in restoring fitness (5). An epidemiological 
study in the South African setting recently showed the presence of rpoA and rpoC mutations 
in the context of transmission of strains harbouring rpoB mutations (6). Evidence suggests that 




a subset of rpoC mutations are associated with a specific rpoB mutation i.e. rpoB Ser531Leu 
(6, 10). However neither of these studies has ruled out other compensatory mechanisms, 
possibly involved in rifampicin resistance. Similarly, mutations in the promoter region of ahpC 
have previously been associated with isoniazid resistance. These mutations have been 
suggested to compensate for the loss of katG activity (11).  
WGS has also been used as a tool to identify novel mechanisms responsible for drug resistance. 
Numerous studies have reported on genetic diversity occurring in M. tuberculosis during the 
evolution of drug resistance (Reviewed by Trauner et al., 2014) (4). While some studies have 
demonstrated genomic stability with low genetic diversity, more recent studies have shown 
high genetic diversity with the emergence of additional genetic variants above those observed 
in drug target genes (4, 12–14). These variants have been identified in several genes involved 
in lipid metabolism, cell wall biosynthesis, purine metabolism, and transcriptional control (4). 
However, the primary focus of the observed genetic variability has been on known drug 
resistance causing mutations. Some studies have demonstrated the acquisition of known 
mutations during the course of infection, highlighting selective evolution during drug treatment 
(15–17), others have investigated the longitudinal fluctuation in mutation frequencies for one 
drug resistance causing gene (18). That study highlighted different aspects of genetic 
variability, but an important conclusion was the importance of investigating sub-populations 
present within in a patient. The presence of sub-populations is a major concern when 
considering the sensitivity of standard genetic tests for the diagnosis of drug resistance in M. 
tuberculosis (19).  
This study aimed to further investigate the in vivo evolution of drug resistance in M. 
tuberculosis, with the overall aim of identifying genetic markers associated with the evolution 
of drug resistance as well as investigating the power of deep sequencing to identify 
heterogeneity within M. tuberculosis populations for diagnostic purposes.  
4.2. Hypothesis 
During the evolution of resistance from rifampicin mono-resistant to MDR, the M. tuberculosis 
genome accumulates additional mutations altering its physiology. 
 





This study aims to investigate the genetic variation between sequential M. tuberculosis isolates 
obtained from individual patients in a South African setting who developed MDR-TB during 
treatment of rifampicin mono-resistant TB. 
Specific aims: 
1. To interrogate the Stellenbosch University M. tuberculosis strain bank to enable the 
identification of serial isolates demonstrating intra-patient evolution of drug resistance. 
2. To use whole genome sequencing to investigate the accumulation of genomic mutations 
occurring during the evolution of MDR-TB. 
4.4. Experimental approach 
Methods used in this study have been detailed in Chapter 2. The experimental approach 
followed in this study is outlined in Figure 4.1 below.  
Figure 4.1 Approach to investigate the accumulation of genomic changes between sequential M. 
Specific aim 1
OUTCOME:
1. Identify paired isolates where M. tuberculosis shows
acquisition of MDR from rifampicin mono-resistance
2. Identification of variants in each isolate relative to
M. tuberculosis H37Rv
3. Identification of variants unique to the MDR isolate
Characterisation of isolates using targeted DNA sequencing, 
spoligotyping and DSTs
Select paired M. tuberculosis clinical isolates originating 
from single patients
Rifampicin mono-resistant            MDR
M. tuberculosis isolates from single 









tuberculosis isolates demonstrating evolution from rifampicin mono-resistance to MDR obtained from 
individual patients in a South African setting.   
4.4. Results 
4.4.1. Interrogation of the Stellenbosch University, Department of Biomedical Sciences 
M. tuberculosis strain bank 
The Department of Biomedical Sciences, Stellenbosch University, has an extensive culture 
bank containing approximately 20 000 M. tuberculosis isolates (both drug resistant and 
sensitive), collected from 2001 to present. These clinical isolates have in part been 
characterised by spoligotyping, targeted DNA sequencing and routine DST. An analysis of the 
M. tuberculosis strain bank was performed based on the available sample information. Patients 
whose samples are available in the strain bank are represented with a unique patient identifier 
(ID); no information about patients is available for research purposes. Patients with more than 
one clinical isolate were selected and analysed to determine the patterns of infection, i.e. a 
patient was infected with a single strain which maintained the same drug resistance profile or 
the strain evolved drug resistance during the course of infection. Figure 4.2 shows the 
breakdown of the samples represented in the strain bank, where multiple samples are available 
for single patients.  
A total of 3354 patients were identified to have multiple samples within the strain bank; 
together these patients have a total of 11286 samples. The drug resistance classification in the 
data base was used to discriminate patients whose samples retained the same drug resistance 
profile throughout infection from those who showed acquisition of drug resistance. Sixty-seven 
percent of patients (2250) with multiple serial isolates retained the same drug resistance profile 
at multiple time points (Figure 4.2). A large percentage of patients (19%) were shown to have 
either mixed infection or re-infection i.e. were infected with multiple strains across serial 
isolates (based on available spoligotyping results) during the course of infection, or they were 
unclassified within the strain bank i.e. no DST or genotypic results were available (Figure 4.2). 
For the purpose of this study the latter samples were excluded from further investigation.  
 





Figure 4.2 Breakdown of the types of sample sets represented in the Stellenbosch University M. 
tuberculosis strain bank. Approximately 67% of patients with sequential samples represented in the 
strain bank were infected with a strain whose drug resistance profile remained constant during the 
course of infection. A further 19% of patients were shown to have mixed infection or a reinfection with 
a different strain, based on spoligotyping results. Approximately 14% of patients were shown to be 
infected with strains which acquired additional drug resistance during the course of infection.  
Approximately 14% of the patients represented in the data base were shown to be infected with 
strains which acquired resistance to additional anti-TB drugs during the course of infection 
(476 patients); a total number of 2830 M. tuberculosis samples are available for these patients 
(Figure 4.2). A breakdown of the types of drug resistance acquisition in clinical isolates 
observed in these patients is shown in Table 4.1. The classification of the drug resistance profile 
is based on DSTs and in some cases line probe assays. The predominant pattern of evolution 
was found to be from MDR to pre-XDR (51.89%). The percentage of patients with strains 
evolving to XDR was 10.71%, while 9.24% of the patient isolates showed the evolution from 
MDR to pre-XDR to XDR.  
Samples demonstrating evolution of resistance from rifampicin mono-resistant to MDR were 
selected and characterised to confirm the reported phenotypes. A total number of 66 samples 












Table 4.1 Patterns of drug resistance evolution represented within the Stellenbosch University strain 
bank from individual patients. 
Pattern of evolution Samples represented in the strain bank  
% (number of patients) 
Rifampicin mono-resistant to MDR 7.35 (35) 
Isoniazid mono-resistant to MDR 9.66 (46) 
MDR to pre-XDR 51.89 (247) 
MDR to XDR 10.71 (51) 
MDR to pre-XDR to XDR 9.24 (44) 
Pre-XDR to XDR 11.13 (53) 
4.4.2. Strain characterisation 
Selected M. tuberculosis isolates were characterised using PCR and Sanger sequencing of 
known drug resistance causing mutations, as well as spoligotyping. The initial screen included 
analysed the inhA promoter, and rpoB and katG genes for resistance-causing mutations 
(Appendix 2, Table A2.1). Eighteen sample sets (38 isolates) with discrepant genotypes 
(according to PCR and sequencing) and phenotypes (according to database) were eliminated 
from further screening since they no longer represented isolate sets demonstrating evolution 
from rifampicin mono-resistant to MDR. Specifically, these isolates were originally classified 
as rifampicin mono-resistant, but contained isoniazid resistance-conferring inhA promoter or 
katG mutations. The remaining 28 isolates were further characterised by PCR and Sanger 
sequencing of the embB, gyrA, rrs and pncA genes. Following this, a further 16 isolates were 
eliminated due to the presence of either gyrA, embB, rrs or pncA mutations (Appendix 2, Table 
A2.2). The remaining 16 isolates were subjected to rifampicin and isoniazid DST, to confirm 
the drug resistant phenotype (Appendix 2, Table A2.3). A total of 6 isolates showed to have 
the correct drug resistance phenotype, 3 rifampicin mono-resistant isolates, each with a paired 
MDR isolate. Serial isolates where the initial isolate was rifampicin mono-resistant and the 
follow-up sample MDR were subjected to spoligotype analysis to confirm that the isolates in 
each set were of the same strain family (Appendix 2, Table A2.4). Serial isolates were 
eliminated if the strain family differed between the rifampicin mono-resistant and MDR 
isolates since this suggested either mixed infections or exogenous re-infection with a different 
strain and the original M. tuberculosis strain responsible for infection had not evolved 
additional resistance to isoniazid.  




A total of 6 isolates, from 3 patients demonstrated in vivo evolution of isoniazid resistance. 
Genotyping of rpoB, katG and inhA promoter as well as the spoligotype for each isolate are 
shown in Table 4.2. Resistance to isoniazid was conferred by mutations in the katG gene or 
inhA promoter for patients 1 and 2 respectively. In contrast, the MDR isolate from patient 3 
(R15213) had no katG or inhA promoter mutations despite phenotypic isoniazid resistance 
suggesting that an alternative mechanism of isoniazid resistance was present (Appendix 2, 
Table A2.4). Table 4.2 summarises the genotypic characteristics of the serial isolates from the 
three patients where intra-patient evolution of isoniazid resistance was observed.  
Table 4.2 Genotypic and phenotypic characterisation of 6 M. tuberculosis isolates originating from 3 








































Leu511Pro - - 

(X-family/LCC) 
*Amino acid change according to the Escherichia coli rpoB gene sequence 
Analysis of the respective spoligotype patterns suggested that the M. tuberculosis strains 
remained the same during the course of the disease. However, given the low discriminatory 
power of spoligotyping for Beijing genotypes as well as the high prevalence of this genotype 
in the Western Cape of South Africa, IS6110 DNA fingerprinting was done to ensure that the 
strain in isolate R721 and R807 were identical and from the same Beijing sub-lineage (Figure 
4.3). The non-Beijing isolates were included in the analysis to confirm spoligotyping results. 
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Figure 4.3 RFLP DNA fingerprinting confirming the paired rifampicin mono-resistant and MDR M. 
tuberculosis isolate from each patient are of the same genetic background. 
In summary, of the 66 samples (from 31 patients) screened a total of 3 pairs of isolates were 
confirmed to show in vivo evolution of MDR (sensu stricto). The 6 isolates comprising these 
3 sets are summarised in Table 4.4.  
Table 4.4 M. tuberculosis isolates demonstrating in vivo evolution from rifampicin mono-resistance to 
MDR. 




R721 22/10/2003 Rifampicin mono-
resistant 
Beijing 
R807 19/05/2004 MDR Beijing 
2 
R912 15/09/2004 Rifampicin mono-
resistant 
EAI 
R1210 12/08/2005 MDR EAI 
3 
R6264 05/07/2009 Rifampicin mono-
resistant 
LCC 
R15213 03/08/2011 MDR LCC 
4.4.3. Whole genome sequencing 
4.4.3.1. Initial whole genome sequencing analysis and quality control 
To investigate the accumulation of genetic variants during the evolution of drug resistance, the 
6 M. tuberculosis clinical isolates (Table 4.3) where sequenced on the IlluminaMiSeq platform. 
FastQC reports (Appendix 3) were generated for each isolate to assess the quality of the 




sequencing data. The genomes of the 6 selected M. tuberculosis isolates (Table 4.3) were 
aligned to M. tuberculosis H37Rv reference genome using 3 mappers. Qualimap reports were 
generated to assess the quality of the alignment and mapping to M. tuberculosis H37Rv 
reference genome (summarised in Table 4.6). The Qualimap report showed the GC content of 
the mapped reads ranged from 64.97 to 66.17%, which correlates to the GC content of M. 
tuberculosis (20). The percentage of mapped reads was high, ranging from 95.46 to 98.47% 
indicating successful alignment and mapping of the Illumina reads to the reference genome.  
Table 4.6 Evaluation of the quality of the mapped sequencing data generated by the IlluminaMiSeq 
platform. 
 R721 R807 R912 R1210 R6264 R15213 
GC Content (%) 64.97 64.86 65.13 65.71 65.66 66.17 
Mapping Coverage (%) 95.46 96.98 98.34 98.29 98.46 98.47 
Number of Reads 
Mapped 
3 799 676 2 930 788 2 851 935 2 430 795 3 175 563 3 490 840 
Mean Read Length (bp) 181.88 177.94 186.72 180.73 168.52 176.63 
Coverage Depth (fold) 143.94 112.25 120.36 98.94 120.85 138.97 
The number of variants identified relative to M. tuberculosis H37Rv using each mapper are 
shown in Table 4.7. A polymorphism was considered to be high confidence if it was identified 













Table 4.7 Number of polymorphisms identified by the 3 mappers used in this study relative to M. 
tuberculosis H37Rv. 
  Patient 1 Patient 2 Patient 3 
 R721 R807 R912 R1210 R6264 R15213 
SNPs 
BWA 2877 2762 3573 3852 2045 2219 
Novoalign 2047 2033 2853 2887 1500 1526 
SMALT 3367 3508 4618 4634 2625 2745 
High 
confidence* 
1703 1722 2532 2543 1204 1227 
InDels 
BWA 184 211 260 281 141 140 
Novoalign 204 206 249 253 143 140 
SMALT 193 223 254 268 143 144 
High 
confidence* 
134 134 161 164 92 81 
*Variants identified in all 3 mappers were considered to be high confidence variants and used for further analyses 
4.4.3.2. Identification of high confidence variants unique to rifampicin mono-resistant and 
MDR isolates 
In order to confirm that the M. tuberculosis isolates collected from the respective patients were 
closely related a phylogenetic tree was constructed using whole genome sequencing data of 
these isolates together with well characterised M. tuberculosis isolates with known assigned 
lineages (Figure 4.3). This phylogenetic analysis showed that the isolates from each patient 
clustered together, confirming clonality as well as the genetic lineage. R721 and R807 clustered 
with isolates belonging to lineage 2 which is also known as the East Asian lineage and includes 
the Beijing genotype (21). R912 and R1210 clustered with isolates belonging to lineage 1 
(Indian Oceanic), which includes isolates belonging to the East Africa India lineage. Similarly, 
R6264 and R15213 clustered with isolates known to belong to lineage 4, classified as Euro-
American. Sub-lineages of lineage 4 include isolates from the following families: Latin 
American Mediterranean (LAM), Family 11 (F11), Low Copy Clade (LCC), T family as well 
as M. tuberculosis reference H37Rv.  





Figure 4.3 Molecular Phylogenetic analysis by Maximum Likelihood method. Branches corresponding 
to partitions reproduced in less than 50% bootstrap replicates are collapsed. The percentage of replicate 
trees in which the associated taxa clustered together in the bootstrap test (1000 replicates) is shown next 
to the branches.  
To identify polymorphisms occurring concomitantly with the evolution of isoniazid resistance 
the genome sequence of the rifampicin mono-resistant isolate was compared to the MDR 
isolate for each patient sample set, i.e. the polymorphisms for each isolate relative to M. 
tuberculosis H37Rv (Table 4.7) for the rifampicin mono-resistant isolate were compared to 
those identified in its paired MDR isolate. Polymorphisms of interest were those found to be 
unique to either the rifampicin mono-resistant or MDR isolate (Table 4.8).  
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Table 4.8 Number of variants identified to be unique to each isolate within a patient sample set relative 
to M. tuberculosis H37Rv. 
  Patient 1 Patient 2 Patient 3 
  R721 R807 R912 R1210 R6264 R15213 
SNPs 
BWA 656 494 347 570 253 470 
Novoalign 117 61 45 85 34 48 
SMALT 464 565 369 348 222 264 
High 
confidence* 
42 10 16 15 4 14 
InDels 
BWA 8 29 21 38 15 13 
Novoalign 8 12 8 13 6 4 
SMALT 14 1 18 35 17 25 
High 
confidence* 
3 1 0 2 0 0 
*Variants identified in all 3 mappers were considered to be high confidence variants 
High confidence polymorphisms were manually inspected using Genomeview 
(www.genomeview.org) to ensure that a polymorphism considered unique to one isolate was 
indeed not present in the paired isolate. Polymorphisms were subsequently filtered based on 
their quality values. In addition, polymorphisms identified in pe_ppe genes were excluded from 
further analysis since these repetitive regions are GC rich and difficult to map efficiently during 
mapping and alignment to the M. tuberculosis H37Rv reference genome.  
Polymorphisms identified as unique to either the rifampicin mono-resistant or MDR isolates 
were validated using targeted PCR and Sanger sequencing (Table 4.9, Table 4.10 and Table 
4.11). Tables 4.9, 4.10 and 4.11 show that the majority of the variants identified were only 
present in a portion of the population with mutant variants being present in as little as 11% of 
the Illumina reads. Sanger sequencing was used to investigate what percentage of a mutant 
population would still be visible on a chromatogram. Figure 4.4 shows representative 
chromatograms demonstrating the ability of Sanger sequencing to detect mutant populations 


























Figure 4.4 Sanger sequencing of wild type and mutant alleles present at varying proportions within the 
M. tuberculosis population. (A) Sanger sequencing chromatogram for Rv1418, where 70% of Illumina 
reads contained the mutant allele. Sanger sequencing scored this as a hetero-variant, denoted by ‘K’ in 
the sequence. (B) Sanger sequencing chromatogram for Rv1629, where 45% of Illumina reads contained 
the mutant allele. Sanger sequencing scored this as the wild type allele. (C) Sanger sequencing 
chromatogram for Rv0667, where 11% of Illumina reads contained the mutant allele. Sanger sequencing 
scored this as the wild type allele. 
For the purpose of this study a polymorphism was considered a polymorphism as fixed when 
it represented in 95% of the Illumina sequencing reads, while a heterogeneous polymorphism 
was defined by a base pair change, insertion or deletion in less than 95% of the reads. For 
patient 1, only one fixed polymorphism was seen in the katG gene in isolate R807, a known 
isoniazid resistance causing mutation. This polymorphism was present in the original screen 
confirming that R807 was an MDR isolate. Numerous heterogeneous polymorphisms were 
observed in both R721 and R807 in genes involved in cell wall metabolism, information 
pathways, intermediary metabolism and respiration as well as in genes encoding conserved 
hypothetical proteins (Table 4.9). For patient 2, while R912 showed to have only fixed 
polymorphisms, the paired MDR isolate, R1210, had only heterogeneous polymorphisms. It is 
interesting to note that the polymorphisms unique to R912 were subsequently not present in 
the population after a period of time (approximately 11 months) (Table 4.10). These 
polymorphisms were also seen in genes involved in cell wall metabolism, information 











Heterogeneous SNPs were also seen in genes encoding conserved hypothetical proteins. For 
patient 3 only heterogeneous polymorphisms were observed to be unique to the respective 
isolates.   




Table 4.9 Variants identified to be unique during the comparison of the rifampicin mono-resistant and MDR M. tuberculosis isolates of patient 1 during the in 
vivo evolution of drug resistance. 







Gene description Functional category$ 
R721* 
SNPs 
Rv0435c  I397L 50 Putative conserved ATPase Cell wall and cell processes 
Rv0435c  D395Y 50 Putative conserved ATPase  
Rv0668 rpoC V1039A 30 
DNA-directed RNA polymerase RpoC 
(RNA polymerase beta' subunit). 
Information pathways 






Intergenic (upstream of a conserved 
hypothetical) 
 
Rv1850 ureC Q11K 48 
Urease alpha subunit UreC (urea 
amidohydrolase) 
Intermediary metabolism and respiration 
Rv1850 ureC Q11R 49 
Urease alpha subunit UreC (urea 
amidohydrolase) 
 
Rv3218  Y174H 66 Conserved protein Conserved hypotheticals 
InDels 
Rv2004c  A - AAG 43 Conserved protein Conserved hypotheticals 
Rv3563 fadE32 A-AC 40 Probable acyl-CoA dehydrogenase FadE32 Lipid metabolism 
Rv3696c glpkK A-AC 73 
Probable glycerol kinase GlpK 
(ATP:glycerol 3-phosphotransferase) 
Intermediary metabolism and respiration 
R807# SNPs 
Rv1908c katG G309V 100 Catalase-peroxidase-peroxynitritase T KatG Virulence, detoxification, adaptation 
Rv0667 rpoB I889V 11 
DNA-directed RNA polymerase RpoB 
(RNA polymerase beta subunit) 
Information pathways 
Rv3696c glpK T91I 80 
Probable glycerol kinase GlpK 
(glycerokinase) (GK) 
Intermediary metabolism and respiration 
*Rifampicin mono-resistant; #MDR; $Functional category as classified by Tuberculist (http://genolist.pasteur.fr/TubercuList/ and http://tuberculist.epfl.ch/ 
Stellenbosch University  https://scholar.sun.ac.za




Table 4.10 SNPs identified to be unique during the comparison of the rifampicin mono-resistant and MDR M. tuberculosis isolates of patient 2 during the in 
vivo evolution of drug resistance. 





Gene description Functional category$ 
R912* 
Rv1128c  G430S 98 Conserved hypothetical protein Insertion seqs and phages 
Rv2236c cobD L269S 97 
Probable cobalamin biosynthesis 
transmembrane protein CobD 
Intermediary metabolism and respiration 
Rv2664  H22Q 99 Hypothetical protein Conserved hypotheticals 
Rv2772c  E149* 97 Probable conserved transmembrane protein Cell wall and cell processes 
Rv2984 ppk1 P631A 96 
Polyphosphate kinase PPK (polyphosphoric 
acid kinase) 
Intermediary metabolism and respiration 
Rv3391 acrA1 syn (248) 99 
Possible multi-functional enzyme with 
acyl-CoA-reductase activity AcrA1 
Lipid metabolism 





-15 45   
Rv0534c menA G219D 20 
1,4-dihydroxy-2-naphthoate 
octaprenyltransferaseMenA 
Intermediary metabolism and respiration 
Rv0669c  D574N 17 Possible hydrolase Intermediary metabolism and respiration 
Rv1459c mptA R36C 25 
Possible conserved integral membrane 
protein 
Cell wall and cell processes 
Rv1484 inhA S94A 70 
NADH-dependent enoyl-[acyl-carrier-
protein] reductase InhA (NADH-dependent 
enoyl-ACP reductase) 
Lipid metabolism 
Rv1629 polA syn (146) 45 Probable DNA polymerase I PolA Information pathways 
Stellenbosch University  https://scholar.sun.ac.za




Rv2935  ppsE C582R  69 Phenolpthiocerol synthesis type-I 
polyketide synthase PpsE 
Lipid metabolism 
*Rifampicin mono-resistant; #MDR;  
$Functional category as classified by Tuberculist (http://genolist.pasteur.fr/TubercuList/ and http://tuberculist.epfl.ch/) 
 
Table 4.11 SNPs identified to be unique during the comparison of the rifampicin mono-resistant and MDR M. tuberculosis isolates of patient 3 during the in 
vivo evolution of drug resistance. 





Gene description Functional category$ 
R6264* Rv1415 ribA2 K170I 7 
Probable riboflavin biosynthesis protein 
RibA2 
Intermediary metabolism and respiration 
R15231# 
Rv0932c pst2 A333E 16 
Periplasmic phosphate-binding lipoprotein 
PstS2 
Cell wall and cell processes 
Rv1362c  syn (163) 8 Possible membrane protein Cell wall and cell processes 
Rv1844c gnd1 G459D 13 
Probable 6-phosphogluconate 
dehydrogenase Gnd1 
Intermediary metabolism and respiration 
Rv1925 fadD31 E126A 11 
Probable acyl-CoA ligase FadD31 (acyl-
CoA synthetase) 
Lipid metabolism 
Rv2016  G1A 11 Hypothetical protein Conserved hypotheticals 
Rv2048c pks12 G1638R 16 Polyketide synthase Pks12 Lipid metabolism 
Rv3043c ctaD syn (382) 11 
Probable cytochrome C oxidase 
polypeptide I CtaD (cytochrome AA3 
subunit 1) 
Intermediary metabolism and respiration 
*Rifampicin mono-resistant; #MDR 
$Functional category as classified by Tuberculist (http://genolist.pasteur.fr/TubercuList/ and http://tuberculist.epfl.ch/)
Stellenbosch University  https://scholar.sun.ac.za




GO enrichment analysis was done using the Rv numbers of the genes where polymorphisms 
were observed in each individual isolate. No common GO terms were specifically enriched in 
each isolate. Similarly when the Rv numbers of the polymorphisms seen in all the rifampicin 
mono-resistant isolates or all the MDR isolates were analysed no GO terms were found to be 
significantly enriched. However, the number of genes of interest may be too small for an 
efficient GO enrichment. In addition, the GO terms may be too refined to identify a pattern on 
a larger scale. Therefore the functional groups used for classification by Tuberculist 
(http://genolist.pasteur.fr/TubercuList/ and http://tuberculist.epfl.ch/) were used to analyse the 
type of polymorphisms identified in this study (Table 4.12). 
Table 4.12 Functional characterisation of high confidence variants unique to rifampicin mono-resistant 
and MDR M. tuberculosis isolates.  
Functional category Total number of 
genes 
Number of genes unique to 
rifampicin mono-resistant 
isolates (%) 
Number of genes 
unique to MDR 
isolates (%) 
Cell wall and cell processes 5 2 (40) 3 (60) 
Information pathways 2 1 (50) 1 (50) 
Conserved hypotheticals 4 3 (75) 1 (25) 
Intermediary metabolism and 
respiration 
9 5 (56) 4 (44) 
Virulence, detoxification, 
adaptation 
1 0 (0) 1 (100) 
Insertion seqs and phages 1 1 (100) 0 (0) 
Lipid metabolism 5 1 (20) 4 (80) 
The number of genes observed in each functional category for this analysis was low. However, 
when comparing the genes containing polymorphisms unique to each isolate it was seen that 
polymorphisms were predominantly observed in MDR isolates in genes involved in cell wall 
and cell processes and lipid metabolism. The highest number of polymorphisms observed in 
the rifampicin mono-resistant isolates was in genes involved in intermediary metabolism and 
respiration; however the proportion of polymorphism in the rifampicin mono-resistant and 
MDR isolates is very similar.  
 
 




4.4.4. Compensatory mutations 
The whole genome sequencing data generated was used to investigate the presence of 
compensatory mutations in each M. tuberculosis isolate (Table 4.13). Isolates R912 and R1210 
retained the same rpoC mutation (Ala172Val) during the course of infection, as well as 2 
synonymous SNP at codons 61 and 173. Similarly, R6264 and R15231 retained the same rpoC 
mutation during the course of infection. These mutations were fixed within the population i.e. 
occurring in more than 95% of the Illumina reads. R721 was found to have an rpoC 
Val1039Ala mutation in 30% of the Illumina reads. This mutation was not present in the 
subsequent MDR isolate (R807), which had acquired an additional rpoB polymorphism 
(I889V) in 11% of the Illumina reads.  
Table 4.13 Mutations identified in the rpoB and rpoC genes in rifampicin mono-resistant and paired 
MDR M. tuberculosis isolates. 
Patient Isolate rpoB rpoC 
1 R721$ Ser531Leu* Val1039Ala 
R807# Ser531Leu*; I889V; 
1075 (syn) 
- 
2 R912$ His526Try*; 1075 (syn) Ala172Val; 61 (syn); 
173 (syn) 
R1210# His526Try*; 1075 (syn) Ala172Val; 61 (syn); 
173 (syn) 
3 R6265$ Leu511Pro* Gly594Glu 
R15231# Leu511Pro* Gly594Glu 
*Amino acid change according to the Escherichia coli rpoB gene sequence 
$Rifampicin mono-resistant; #MDR 
4.4.5. Department of Biomedical Sciences Genome bank analysis 
The Department of Biomedical Sciences has a genome bank of approximately 400 M. 
tuberculosis clinical isolates (at the time of submission) which have been whole genome 
sequenced. This collection includes both drug sensitive and resistant isolates. The genes of 
interest identified in this study (Tables 4.9, 4.10 and 4.11) were investigated in this genome 
bank to determine the possible clinical relevance of polymorphisms in these genes. The 
majority of the polymorphisms identified in this study were only present in the M. tuberculosis 
isolates investigated, with the exception of the polymorphism identified in Rv0932 (pst2) 
(Ala333Glu). This polymorphism was present in 11 M. tuberculosis isolates in the genome 




bank, all of which are isoniazid resistant. In addition, the polymorphism identified in Rv1484 
(inhA) (Ser93Ala) was shown to be present in 6 MDR M. tuberculosis isolates. However, an 
additional 15 isoniazid resistant M. tuberculosis isolates were found to have a different 
polymorphism in this gene (Ile194Thr). A final gene of interest highlighted in this analysis was 
Rv0534. The polymorphism identified in this study (Table 4.10) was only present in R1210, 
however a polymorphism at codon 219 (Gly219Asp) of this gene was seen in 33 drug resistant 
isolates and no drug sensitive isolates.  
4.5. Discussion 
Alarmingly, 14% of the patients represented in the data base showed to be infected with strains 
which showed the evolution of additional drug resistance during the course of infection. 
However, this may be an under-estimate given that routine drug susceptibility testing is limited 
to only 4 anti-TB drugs and many of the cases had only a single cultured isolate. In addition, 
there may be patients who never returned for follow up sample collection, these would 
therefore be excluded from this 14%. This clearly indicates that treatment may be inefficient 
in numerous patients, given that additional resistance is acquired during the course of infection. 
Mixed infection was also observed in a large number of patient isolates indicating possible 
exogenous re-infection. This finding reflects the high infection pressure of drug resistant TB 
in communities ravaged by TB as well as nosocomial transmission in healthcare facilities. 
Analyses of the patient isolates showing acquisition of drug resistance allowed for the 
generation of a list of M. tuberculosis isolates which may be used to investigate the in vivo 
evolution of drug resistance, focusing on numerous evolutionary paths i.e. mono-resistance 
evolving to MDR, MDR evolving pre-XDR and subsequent XDR as well as MDR evolving 
XDR. This study focused on the evolution of MDR M. tuberculosis isolates from rifampicin 
mono-resistant progenitor isolates.   
Our analysis of rifampicin resistant cases which progressed to MDR-TB highlighted the 
inaccuracy of routine DST. Our strain bank was shown to have a total of 66 isolates from 31 
patients demonstrating evolution from rifampicin mono-resistance to MDR infection. 
However, subsequent confirmation of genotypic and phenotypic drug resistance, as well as 
spoligotyping (in a few instances) highlighted the gross inaccuracy of the data for the samples 
represented in the strain bank – at least for isoniazid which is one of the easier drugs to test. 
This highlights the potential laboratory error and inaccuracy of the standardised diagnostics 
and/or data capturing error. Our observation that many of the isolates had resistance to 




additional drugs beyond MDR is of additional concern as these patients would have received 
in appropriate MDR treatment. This would impact the period of infectiousness as well as 
treatment outcome with the potential for developing XDR-TB.  
The results of this study highlight the importance of including genetic testing in the diagnosis 
of TB disease. Genotypic analysis resulted in the identification of a number of isolates with 
additional resistance. The simplicity of genetic testing would enable routine laboratories to 
process higher number of samples with less biohazard exposure.  
In depth interrogation of the genomes of the three pairs of serial isolates that the genome of M. 
tuberculosis is dynamic during the course of infection. Our hypothesis expected that the MDR 
isolates would contain unique polymorphisms relative to the rifampicin mono-resistant 
isolates, however numerous polymorphisms were observed to be unique in each mono-resistant 
isolate. The disappearance of these polymorphisms during the emergence of resistance suggests 
they were not providing a selective advantage during the growth of M. tuberculosis under the 
selective pressure of the host and drug. If these patients were on first-line therapy and thereby 
were exposed to isoniazid, individual bacilli within the M. tuberculosis population which 
harboured either a katG or inhA mutation would be expected to dominate. Consequently, 
polymorphisms observed in the rifampicin mono-resistant isolate were ‘lost’ from the 
population and polymorphisms unique to the bacilli that gained isoniazid resistance were 
enriched. The treatment information for each patient at the time of sample collection is not 
available, however based on standard treatment protocols it can be assumed that the patients 
remained on first line treatment after the collection of the initial rifampicin mono-resistant 
sample. The policy guidelines in place for the management of Directly Observed Treatment 
Short course (DOTS) state that patients infected with mono-resistant M. tuberculosis should 
remain on standard first-line therapy (http://www.sahealthinfo.org/tb/mdrtbguidelines.pdf).  If 
this was the case for these 3 patients, it reflects the incorrect implementation of the treatment 
guidelines with the consequence of amplification of drug resistance. 
M. tuberculosis responsible for disease in Patient 1 acquired a katG mutation conferring 
isoniazid resistance, while the causative M. tuberculosis isolate in patient 2 acquired an inhA 
promoter mutation. Both of these mutations are regarded as high confidence mutations 
conferring isoniazid resistance. Interestingly, the M. tuberculosis MDR isolate for Patient 3 did 
not acquire any mutations in katG or the inhA promoter region. Phenotypic tests showed this 
isolate to be resistant to isoniazid using a critical concentration of 1μg/ml. The paired isolates 




from patient 3 were therefore included for whole genome sequencing analysis with the aim of 
identifying the mechanism of isoniazid resistance. No known isoniazid resistance causing 
mutations were observed (ahpC, ndhA, kasA) in the sequencing data of R15213. However a 
polymorphism was observed in pst2 which has previously been associated with isoniazid 
resistance in M. tuberculosis isolates with no known resistance causing mechanism (22). 
Furthermore, analysis of approximately 400 M. tuberculosis genomes showed that the 
polymorphism identified in this study is present in 11 other isoniazid resistant M. tuberculosis 
clinical isolates. Of these, approximately half the isolates contained either a katG or inhA 
promoter mutation. This observation supports the potential role of a mutation in pst2 in 
contributing to isoniazid resistance. Further studies will be required to determine whether this 
pst2 polymorphism does indeed result in isoniazid resistance.  
Whole genome sequencing analysis was used to identify compensatory mutations in the rpoC 
gene in the M. tuberculosis isolates analysed in this study. For the M. tuberculosis isolates from 
patients 2 (R912 and R1210) and 3 (R6264 and R15231) the rpoC mutation remained constant 
during the course of infection. However, the mutations present in rpoC in these isolates 
(Ala172Val and Gly594Glu) were previously shown to be present in both rifampicin sensitive 
and resistant isolates and thereby are not considered to be compensatory mutations (8). In 
addition, R912 and R1210 both harboured an additional polymorphism in rpoB (A1075A), 
which has also been identified as a phylogenetic marker and therefore has no role in 
compensating for loss of fitness (8). For patient 1 the rifampicin mono-resistant isolate (R721) 
was shown to have an rpoC (Val1039Ala) mutation in approximately 30% of the Illumina 
reads. This mutation was not observed in the paired MDR isolate (R807); the MDR isolate 
contained an additional rpoB mutation (Ile889Val) in 11% of the Illumina reads. Neither of 
these mutations has previously been identified in literature. Similarly, analysis of the 
Department of Biomedical Sciences genome bank revealed that neither of these polymorphisms 
are present in the available clinical M. tuberculosis isolates, suggesting that these 
polymorphisms are transient and do not allow for any fitness advantage in M. tuberculosis.  
A principle finding of this study was the range of genes with polymorphisms which were 
observed to emerge and disappear in during the course of infection. Previous studies have 
reported additional mutations occurring concurrently with drug resistant causing mutations (4, 
12–14). These variants have been identified in several genes involved in lipid metabolism, cell 
wall biosynthesis, purine metabolism, and transcriptional control (4). Numerous 
polymorphisms have previously been identified to be ancillary to drug resistance i.e. provide 




an optimal physiological environment for a particular drug resistance phenotype (4). For 
example, genes involved in polyketide synthesis have been hypothesised to be ancillary to 
rifampicin resistance (4, 23). In this study polymorphisms where seen in ppsE (encoding 
Phenolpthiocerol synthesis type-I polyketide synthase PpsE) and pks12 (encoding polyketide 
synthase 12). Mycobacterium avium-intracellulare and Mycobacterium bovis pks12 knockout 
strains have been shown to be more susceptible to multiple anti-TB compounds (24), while 
ppsA (a component in the PDIM biosynthetic pathway) has been shown to be up regulated in 
rifampicin resistant isolates. ppsE is proposed to be involved in the same pathway as ppsA.  In 
this study it was also noted that polymorphisms unique to the MDR isolates were 
predominantly seen in genes involved in cell wall and cell processes or lipid metabolism. Farhat 
et al recently suggested that remodeling of the cell wall may play an important role in stable 
drug resistance phenotypes (23). Our findings support this idea, demonstrating the acquisition 
of mutations in genes involved in cell wall remodeling.  
While the findings of these studies may all identify the acquisition of additional mutations 
during the course of infection, this is the first study to identify heterogeneous polymorphisms 
in genes involved in many metabolic processes. Heterogeneity has recently been investigated 
for drug resistance causing genes, focusing on the implications for genetic testing. Sun et al 
demonstrated a fluctuation in the mutation frequency of various drug resistance causing genes 
as well as in genes not associated with drug resistance (18). In a separate study the presence of 
sub-populations was highlighted using a whole genome sequencing approach (15), and the 
present study complements these findings. In this study high genetic diversity was seen 
between serial isolates, during the evolution of drug resistance. While some fixed 
polymorphisms were observed, there were many heterogeneous polymorphisms. This 
highlights the presence of sub-populations that are present within a patient at a single time 
period, and how these populations are adapting and changing over time. Based on these 
findings we propose a model for the evolution of drug resistance in M. tuberculosis (Figure 
4.5), where numerous genes may contain heterogeneous polymorphisms at time point 1, with 
1 fixed drug resistance causing mutation. The physiological consequences of the heterogeneous 
polymorphisms remain unknown. During the course of infection, under host pressure, some 
polymorphisms may emerge, while others are lost from the population. This variation in 
genome may depend on the environmental pressure encountered within the host. Under 
selective drug pressure, drug resistance causing mutations may emerge. This would result in a 































different individual predominating in the population at a second time point. Again, numerous 






Figure 4.5 Proposed model for the evolution of M. tuberculosis. After the onset of infection, host 
pressure acts on M. tuberculosis. Certain polymorphisms emerge or disappear, never becoming fixed 
within the M. tuberculosis population while others become fixed e.g. drug resistance causing mutations. 
It remains unknown how many individual populations are present at one time point or if specific 
polymorphisms occur together with other mutations or alone i.e. mutations in gene A and B may occur 
within the same individual within a population.  
While this study highlighted that the M. tuberculosis genome is dynamic, it was unable to 
identify markers associated with the evolution of drug resistance. All three sample sets were of 
a different genetic background and direct comparison between each set was therefore not 
possible. It is likely that a larger set of isolates including numerous samples from each strain 
family will increase the likelihood of identifying markers for the evolution of drug resistance. 
However, the pattern of evolution observed in all three isolates was the same i.e. 
polymorphisms emerge and disappear during the course of infection regardless of strain family. 
Additional samples for each patient would also have been advantageous, providing the means 
to determine if there are specific heterogeneous polymorphisms which may become fixed in 
the population or if the genome remains in a dynamic state. This limitation may be overcome 
by investigating a different pattern of drug resistance evolution. This study has identified 
samples from patients which show multiple evolutionary patterns which may be used for future 
studies. For example, there are 375 samples originating from 44 patients demonstrating 
evolution from MDR to pre-XDR and subsequent XDR. In addition, a more comprehensive 
study which includes proteome and transcriptomic analysis may provide information on the 
physiological consequences of the genomic changes observed during the evolution of 
resistance.  




In conclusion, this study has demonstrated the dynamics of the genome of M. tuberculosis 
during the course of infection and during the evolution of drug resistance. The identification of 
heterogeneous polymorphisms present in the M. tuberculosis population at low frequencies 
highlights the quantitative capacity of deep sequencing, a tool which should be exploited for 
the design of future diagnostic tests.  
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The role of efflux pumps in the evolution of drug resistance in Mycobacterium tuberculosis 
  





Active efflux is commonly understood to contribute to drug resistance in numerous bacteria 
and has been thoroughly reviewed (1–3). There is also an increasing body of evidence 
highlighting the contribution of efflux pump systems in Mycobacterium tuberculosis to drug 
resistance and drug tolerance (discussed in Chapter 2) (4). Tolerance represents a physiological 
state which enables bacterial survival in the presence of antibiotic treatment; following removal 
of the drug(s), active growth is resumed as is fully drug susceptibility (5). While poorly 
understood, it is generally thought that drug tolerance is a result of a physiological response to 
external stimuli, rather than as a result of resistance causing mutations (6). 
It is known that exposure to certain anti-TB drugs induces tolerance in M. tuberculosis; the 
mechanism of which has been linked to efflux pump activity (7–10). However, a recent study 
demonstrated that macrophage infection induced tolerance to anti-TB drugs (7). Upon further 
investigation it was shown that this tolerance in this model could be reversed with the addition 
of efflux pump inhibitors, confirming the role of efflux pump activity in the induction of 
tolerance. More alarming are the results of a follow-up study where it was observed that 
macrophage-induced tolerance negatively affected the activity of newer anti-TB compounds 
(favourable for their ability to shorten treatment regimens) such as moxifloxacin, PA-824, 
linezolid and bedaquiline (11). In addition, recent studies have highlighted the contribution of 
efflux pump activity to low level phenotypic drug resistance, or tolerance i.e. increased levels 
of resistance with no known drug resistance causing mutations (12, 13). This low level drug 
tolerance provides an opportunity for M. tuberculosis to develop drug resistance causing 
mutations, resulting in clinical resistance. Efflux pump activity has therefore been suggested 
to be a gateway mechanism for the development of drug resistance (discussed in detail in 
Chapter 2) (4). Furthermore, recent studies have investigated the role of efflux pump activity 
in cross-resistance between anti-TB compounds (14–16). This phenomenon requires additional 
research in an era where resistance to anti-TB drugs is developing at rapid rates, especially 
when considering that efflux-mediated cross resistance has been shown for promising new anti-
TB drugs such as bedaquiline (14, 17).  
With knowledge of the contribution of efflux pump activity to drug resistance and/or tolerance 
in M. tuberculosis there has been an increased focus on the use of efflux pump inhibitors as a 
complementary TB treatment. Numerous studies have shown the efficacy of including efflux 
pump inhibitor verapamil in treatment regimens; this calcium channel antagonist has been 




shown to shorten treatment of susceptible and MDR infection in mice (11, 18, 19). It has been 
shown that due to the induction of CYP3A4 system by rifampicin, verapamil serum 
concentrations may be reduced by up to 10-fold (20, 21), fuelling the investigation into 
verapamil analogues. Recently verapamil analogues have been shown to have increased 
synergy with rifampicin and comparable activity with verapamil (18).  
The influence of the genotypic characteristics of M. tuberculosis on efflux pump inhibitor 
efficacy has previously been considered. In a study investigating ofloxacin tolerance in M. 
tuberculosis, Louw et al. hypothesised that the differential response seen between isolates was 
due to the presence of different rpoB mutations, that M. tuberculosis isolates harbouring 
different rpoB mutations may have different transcriptomes and certain genes may be 
differentially expressed (22). A follow-up study by our research group showed a substantial 
difference in transcriptional profiles when comparing rpoB Ser531Leu and His526Tyr in vitro 
generated mutants (J du Plessis, M.Sc thesis 2013). In a separate study, Adams et al. 
hypothesised that the efflux pump inhibitors may be more effective on strains over-expressing 
efflux pumps and their efficacy may therefore be strain-dependent (11). There is therefore a 
gap in the knowledge on the efficacy of efflux pump inhibitors on strains with different 
genotypic profiles. No studies have compared the response of M. tuberculosis isolates from 
different genetic backgrounds to efflux pump inhibitor treatment. A broader approach has 
previously been followed with respect to the role of efflux pumps in rifampicin resistance 
specifically. Numerous studies have investigated the transcriptional response of efflux pumps 
to rifampicin exposure in M. tuberculosis isolates with the most prominent rpoB mutations 
(Ser531Leu and His526Tyr), however no direct comparison has been made between M. 
tuberculosis isolates harbouring an rpoB Ser531Leu and His526Tyr with respect to the role of 
efflux pumps in rifampicin resistance.  
In addition, it is unknown whether other genomic changes may also alter the efficacy of efflux 
pump inhibitors i.e. does the acquisition of mutations alter the physiology of M. tuberculosis? 
Recent studies have investigated the genomic changes that occur in serial patient isolates 
(discussed in Chapter 4), but there has been little investigation into the physiological 
consequences of these genetic changes. One such study compared the whole transcriptome of 
paired susceptible and MDR M. tuberculosis isolates from single patients; up-regulation of 
specific efflux pumps, ABC transporters and membrane proteins was shown in the MDR 
isolates when compared to a susceptible ‘progenitor’ isolate (23). This up-regulation of 
transporters was coupled with down-regulation of general cellular metabolism, allowing the 




authors to hypothesise that this may be responsible for low level resistance to numerous anti-
TB drugs and that further drug exposure may select for drug resistance causing mutations (23). 
These findings highlight the potential role of efflux pumps in the evolution of drug resistance. 
However, little research has expanded on these recent findings or investigated the physiological 
changes associated with only the acquisition of one additional drug resistance causing 
mutation. For example, is this phenomenon associated with acquisition of single mutations or 
will up-regulation only be observed in an M. tuberculosis isolate which has accumulated 
numerous mutations?   
5.2. Hypotheses 
The contribution of efflux pump activity to drug resistance differs between M. tuberculosis 
isolates with different genetic backgrounds and rpoB mutations. In particular we hypothesise 
that: 
1. Efflux pump activity contributes to the level of rifampicin resistance in M. tuberculosis.  
2. The contribution of efflux pump activity to drug resistance is altered during the 
acquisition of drug resistance in M. tuberculosis. 
3. Rifampicin resistant M. tuberculosis isolates with different rifampicin resistance 
causing mutations may display differential efflux pump activity.  
5.3. Aims 
This study aims to determine the role of efflux pump activity in drug resistant M. tuberculosis 
isolates. 
Specific aims: 
1. To investigate the role of efflux activity in the evolution of drug resistance. 
2. To determine if genetic background or specific rpoB mutations influence the role of 
efflux pumps in drug resistance (i.e. the activity of efflux pumps and/or the influence 
of verapamil of the level of drug resistance). 
3. To investigate the influence of different rpoB mutations on efflux pump activity in M. 
tuberculosis, with specific focus on rifampicin and ofloxacin levels of resistance. 
 
 




Select paired M. tuberculosis clinical isolates originating from 
single patients
Effect of verapamilon growth in 10μg/ml rifampicin
Rifampicin MIC determination
OUTCOME:
1. To determine the influence of efflux pump
inhibitor verapamil on the growth of rifampicin
resistant M. tuberculosis isolates at a clinically
relevant rifampicin concentration
2. Determine if efflux pump activity changes
during the acquisition of drug resistance
3. To determine if the constitutive expression
of efflux pumps changes during the acquisition





1. Determine if genetic background influences the
response to verapamil i.e. the activity of efflux pumps
2. Determine if specific rpoB mutations influence the
response to verapamil i.e. the activity of efflux pumps
OUTCOME:
1. Determine if specific rpoB mutations influence the
role of efflux pumps in rifampicin levels of
resistance
2. To compare the constitutive expression of efflux
pumps in M. tuberculosis isolates with different rpoB
mutations
qRT PCR efflux pump expression analysis
M. tuberculosis clinical isolates and in vitro generated mutants 
with different rifampicin resistance causing mutations (rpoB)
M. tuberculosis clinical isolates with different genetic 
backgrounds
Rifampicin mono-resistant            MDR
+ Verapamil - Verapamil
+ Verapamil - Verapamil
Rifampicin MIC determination
+ Verapamil - Verapamil
M. tuberculosis clinical isolates and in vitro generated 
mutants with different rpoB mutations
Rifampicin MIC determination
qRT PCR efflux pump expression analysis
5.4. Experimental approach 
Methods used in this study have been detailed in Chapter 3. The experimental approach 























Figure 5.1 Approach to elucidate the role of efflux pumps in drug resistance in closely related M. 
tuberculosis isolates  





5.5.1. The role of efflux pump activity in the evolution of drug resistance in M. tuberculosis 
M. tuberculosis isolates identified in Chapter 4 were selected to represent the 
evolution/acquisition of drug resistance from rifampicin mono-resistant to MDR in this study 
(Table 5.1).  






















R1210 EAI MDR His526Tyr -15 inhA promoter 
*Amino acid change according to the Escherichia coli rpoB gene sequence 
The growth of each isolate was monitored during exposure to 10µg/ml rifampicin, in the 
presence and absence of verapamil (Figure 5.2 and 5.3). The selected rifampicin concentration 
of 10µg/ml reflects a clinically relevant concentration as serum concentrations have been 
shown to range from 8 to 24µg/ml in some patients (24–27). M. tuberculosis growth in the 
BACTEC MGIT™ 960 vials was measured by an increase in fluorescence, as an oxygen 

























































































Figure 5.2 Growth of closely related (A) rifampicin mono-resistant (R721) and (B) MDR (R807) M. 
tuberculosis clinical isolates from patient 1, in the presence and absence of verapamil. The highlighted 
regions indicate the time at which the 1:100 growth controls measured as 400 growth units, the point at 
which the percentage of susceptibility restored by verapamil was calculated.  
Figures 5.2A and 5.3A show that verapamil treatment delays the onset of growth (as a reflection 
of oxygen consumption) of M. tuberculosis isolates R721 and R921 in the presence of 
rifampicin, respectively. This suggests that verapamil does not restore susceptibility to 
rifampicin indefinitely. A similar effect was observed for the MDR isolates R807 and R1210 









Figure 5.3 Growth of closely related (A) rifampicin mono-resistant (R912) and (B) MDR (R1210) M. 
tuberculosis clinical isolates from patient 2, in the presence and absence of verapamil. The highlighted 
(A) (B) 
(A) (B) 








































































































regions indicate the time at which the 1:100 growth controls measured as 400 growth units, the point at 
which the percentage of susceptibility restored by verapamil was calculated.  
The percentage of restored susceptibility to rifampicin, due to verapamil treatment ranged from 
13 to 72% for the rifampicin mono-resistant isolates and 0 to 47% for the MDR isolates (Table 
5.2, Figure 5.4). This value was calculated at the time that the 1:100 growth control of the 
experiment reached 400 growth units, the time at which an experiment is evaluated for standard 
DST (indicated in Figures 5.2 and 5.3). Verapamil restored susceptibility to rifampicin by up 
to 72% in the rifampicin mono-resistant isolate in patient 1 (R721), while only restored 
susceptibility by up to 13% in the rifampicin mono-resistant isolate from patient 2 (R912). 
Similarly, verapamil had a larger effect on the MDR isolate from patient 1 (R807) when 
compared to that of patient 2 (R1210).  
Table 5.2 Percentage of susceptibility to rifampicin by verapamil in M. tuberculosis clinical isolates. 







When comparing the effect of verapamil treatment on clinical isolates from a single patient it 
was observed that there was no significant difference between the rifampicin mono-resistant 
and MDR isolates. This was the case for isolates from both patient 1 and 2. However, a 
differential response to verapamil between rifampicin mono-resistant isolates R721 and R912 
was found to be significant at the time point when a standard DST would be scored (Figure 
5.4). Similarly, the percentage of rifampicin susceptibility restored by verapamil was 


















































Figure 5.4 Restoration of rifampicin susceptibility by efflux pump inhibitor verapamil in rifampicin 
mono-resistant and MDR M. tuberculosis clinical isolates. *statistically significant difference (p<0.05) 
The rifampicin MIC was subsequently determined for each isolate in the presence and absence 
of verapamil (Table 5.3) to determine the influence of verapamil on the level of rifampicin 
resistance.  
Table 5.3 Change in the level of rifampicin resistance in closely related M. tuberculosis isolates in the 
presence of efflux pump inhibitor verapamil.  















120 30 4 





100 100 0 
R1210 MDR 100 100 0 
 
The MIC values for each isolate originating from the same patient remained unchanged during 
the acquisition of isoniazid resistance: 120μg/ml for R721 and R807 and 100μg/ml for R912 
and R1210. However, the level of resistance to rifampicin was different between the rifampicin 
mono-resistant isolate (R721) and MDR isolate (R807) from patient 1 in the presence of 
verapamil. Verapamil treatment resulted in a 4-fold decrease in MIC for R721, but only a 2-




fold decrease in R807. Verapamil treatment showed no effect on the rifampicin MIC for the M. 
tuberculosis isolates from patient 2.  
The expression levels of a panel of efflux pump encoding genes were investigated to compare 
the levels of gene expression between the rifampicin mono-resistant and MDR paired isolates 
from each patient. Table 5.4 shows no significant differential expression of efflux pump genes 
between rifampicin mono-resistant and MDR isolates from individual patients (where 
significance is defined at a fold change >2 and a p value < 0.05). While Rv1819c and mmpL5 
were shown to be up regulated by 5.50 and 3.72 fold respectively, this result was not considered 
significant since the p value was not <0.05. 
Table 5.4 Differential expression of efflux pump genes between rifampicin mono-resistant and MDR 




EmrB Rv3728 PstB DrrA Rv1819c mmpL5 
Patient 1 Ser531Leu 1.59 -0.47 0.42 1.33 1.50 1.41 
Patient 2 His526Tyr -1.42 1.83 -1.98 1.62 5.50 3.72 
*Amino acid change according to the Escherichia coli rpoB gene sequence 
These results show that verapamil delays the onset of growth in the presence of rifampicin, at 
a clinically relevant concentration. In addition it was observed that verapamil has a more 
pronounced effect on certain isolates, decreasing their MIC by up to 4-fold, whereas in others 
there is no fold change. There was no statistically significant fold change in the expression of 
efflux pump genes between the rifampicin mono-resistant and MDR isolates. 
5.5.2. Determination of the role of genetic background and rpoB mutation type on efflux 
pump activity in M. tuberculosis 
In order to investigate the role of genetic background and rpoB mutations on efflux pump 
activity a panel of rifampicin mono-resistant M. tuberculosis clinical isolates from the Beijing 
and EAI strain genotypes were selected. Two isolates were selected for each genotype, each 
with a different rpoB mutation (Table 5.5).  
 




Table 5.5 Characteristics of M. tuberculosis isolates selected to investigate the role of genetic 






Drug resistance profile 
R721 Beijing Ser531Leu Rifampicin mono-resistant 
R966 Beijing His526Tyr Rifampicin mono-resistant 
R5608 EAI Ser531Leu Rifampicin mono-resistant 
R912 EAI His526Tyr Rifampicin mono-resistant 
R160 LCC Ser531Leu Rifampicin mono-resistant 
*Amino acid change according to the Escherichia coli rpoB gene sequence 
The rifampicin MIC was determined for each isolate in the presence and absence of verapamil 
(Table 5.6 and 5.7). One LCC rifampicin mono-resistant M. tuberculosis isolate with an rpoB 
Ser531Leu mutation was included in this study (Table 5.5). A LCC rifampicin mono-resistant 
isolate with an rpoB His526Tyr was not available for use in this study.  
Table 5.6 Change in the level of rifampicin resistance in M. tuberculosis clinical isolates from 
different genetic background with an rpoB Ser531Leu mutation in the presence of efflux pump 








in the presence 
of verapamil 
(µg/ml) 
Fold change in 
MIC 
R721 Beijing 120 30 4 
R5608 EAI 80 20 4 
R160 LCC 120 60 2 
Each of the M. tuberculosis isolates with an rpoB Ser531Leu mutation showed a response to 
verapamil treatment, with a 2- to 4- fold decrease in MIC. Conversely, M. tuberculosis isolates 
with an rpoB His526Tyr mutation showed no response to verapamil treatment with regards to 
a decrease in MIC (Table 5.7). 
 




Table 5.7 Change in the level of rifampicin resistance in M. tuberculosis clinical isolates from different 









in the presence 
of verapamil 
(µg/ml) 
Fold change in 
MIC 
R966 Beijing 50 50 0 
R912 EAI 100 100 0 
The data presented in Tables 5.3, 5.6 and 5.7 suggest that rpoB mutation type and not genetic 
background may be important in defining the response to verapamil treatment. These clinical 
isolates are not closely related and their similar response to verapamil across different genetic 
backgrounds supports the notion that the rpoB mutation defines the response to verapamil 
treatment.  
5.5.3. Influence of different rpoB mutations on efflux pump activity in M. tuberculosis 
To further investigate the role of different rpoB mutations on efflux pump activity the effect of 
verapamil on the rifampicin MIC of in vitro generated rifampicin mono-resistant M. 
tuberculosis isolates was determined (Table 5.8). The isolates containing an rpoB Ser531Leu 
and His526Tyr mutation were generated from a common progenitor M. tuberculosis clinical 
isolate. This strategy allows for a “clean” experiment, excluding the influence of other genetic 
factors which may play a role in clinical M. tuberculosis isolates. 
Table 5.8 Change in the level of rifampicin resistance in M. tuberculosis in vitro generated rifampicin 







in the presence 
of verapamil 
(µg/ml) 
Fold change in 
MIC 
K636.1 Ser531Leu 80 40 2 
K636.2 His526Tyr 200 200 0 




Confirming the results seen in Tables 5.6 and 5.7, Table 5.8 shows that verapamil results in a 
2-fold decrease in rifampicin MIC in the in vitro generated mutant with an rpoB Ser531Leu 
mutation, while it has no influence on the level of resistance of the rpoB His526Tyr mutant.  
These results support the notion that specific rpoB mutations result in a differential response 
to efflux pump inhibitor verapamil, where M. tuberculosis isolates with an rpoB Ser531Leu 
mutation are more susceptible to verapamil treatment when compared to M. tuberculosis 
isolates with an rpoB His526Tyr mutation.  
To further investigate this observation the expression of a panel of efflux pumps was analysed 
using RT-qPCR, comparing the isolate with the rpoB Ser 531Leu mutation and the rpoB 
His526Tyr mutation with the common pan susceptible progenitor (Table 5.9).  
Table 5.9 Differential gene expression of M. tuberculosis in vitro generated rifampicin resistant mutants 
compared to their shared pan-susceptible progenitor isolate. 
 EmrB Rv3728 PstB DrrA Rv1819c mmpL5 
K636.1 -1.37 -7.57* -1.79 -2.42 1.20 -2.46 
K636.2 -2.22* -1.80 -1.94 -2.41 -1.47 1.46 
*P<0.05 
In comparison to the pan-susceptible progenitor, no significant up-regulation of efflux pump 
genes was observed. One efflux pump, Rv3728, was significantly down-regulated in K636.1. 
Significant down-regulation was defined as a fold-change of >2 and a p-value <0.05. This 
isolate harbours a Ser531Leu rpoB mutation. Similarly, one efflux pump, EmrB, was 
significantly down-regulated in K636.2 (harbouring a His526Tyr rpoB mutation). These results 
do not correlate with observed effect of verapamil on rifampicin MIC, suggesting that the 
expression of efflux pumps contributing to the MIC is a response to the presence of rifampicin 
and is not due to constitutive efflux expression i.e. rifampicin exposure induces the up-
regulation of efflux pump activity subsequently influencing the rifampicin MIC.  
These results confirm the observation verapamil has a differential effect on M. tuberculosis 
isolates harbouring different rpoB mutations. In addition, it was observed that there is little 
significant different in efflux pump expression between in vitro M. tuberculosis mutations 
harbouring different rpoB mutations.  





Due to the increasing emergence and spread of drug resistant M. tuberculosis there is an 
increased focus on identification of new anti-TB drug targets, as well as design of optimised 
treatment regimens for improving the length and efficacy of TB treatment. One approach has 
been to develop new compounds with novel targets; however bedaquiline is the first new anti-
TB drug to be approved for used in patients in 40 years (29). Alternately repurposing of 
compounds traditionally used elsewhere has shown great success. Verapamil, a calcium 
channel antagonist, has traditionally been used for treatment of cardiovascular disease but have 
recently shown great promise as a complementary treatment for the current anti-TB regimens. 
While numerous efflux pump inhibitors have been used to investigate efflux activity in M. 
tuberculosis, verapamil is the most promising inhibitor under consideration for inclusion in 
treatment regimens. Adams et al. state that verapamil is the most appealing efflux pump 
inhibitor since it is already approved by the FDA and is well tolerated in humans (11, 17).  
Verapamil had been shown to inhibit bacterial efflux systems (3), which have been the focus 
of a large body of research in recent years due to their role in defining the levels of drug 
resistance, as well their role in drug tolerance (22,31). Numerous studies have shown the 
efficacy of verapamil in improving the treatment regimens, in in vitro studies and in vivo mice 
studies (11, 18, 19, 30).  
Major findings demonstrated the power of verapamil in inhibiting efflux mediated macrophage 
induced tolerance, a mechanism considered to be a gate-way mechanism to the development 
of drug resistance causing mutations (4, 11). In addition, verapamil has been shown to shorten 
the treatment period of the standard regimen with regards to bactericidal and sterilizing activity 
(18, 19). The results of our study complement these findings, demonstrating that at clinically 
relevant rifampicin concentrations, the onset of growth is delayed in the presence of verapamil. 
This may have implications during treatment, with the delay in growth caused by verapamil 
allowing anti-TB compounds time to act on their targets. This is an important observation since 
numerous compounds have been suggested to be extruded from the cell by efflux pumps, 
allowing the mycobacterial cell to stabilise in the presence of drugs during the development of 
resistance causing mutations (12, 13).  
However, while this study demonstrated the ability of verapamil to delay the onset of growth 
at clinically relevant concentrations of rifampicin a startling observation was the differential 




effect this treatment had on M. tuberculosis rifampicin resistant isolates with different rpoB 
mutations. Previous studies in our research group have focused on the difference between M. 
tuberculosis isolates harbouring different rpoB mutations with respect to varying levels of 
rifampicin resistance; the main rpoB mutations of interest on the most prominent clinical 
isolates in South Africa: Ser531Leu and His526Tyr. A main observation has been the delay in 
the induction of ofloxacin tolerance in isolates with an rpoB 526 mutation when compared to 
a 531 mutation. Induction of tolerance was observed in M. tuberculosis isolates harbouring an 
rpoB531 mutation after only 24 hours of rifampicin exposure, while isolates with an rpoB526 
mutation showed only a minor change in ofloxacin MIC after a 7 day period (22). These 
findings led to additional studies which demonstrated that M. tuberculosis in vitro generated 
mutants harbouring different rpoB mutations had a vastly different transcriptional profile with 
genes involved in intermediary metabolism and respiration as well as cell wall and cell 
processes significantly differentially expressed between isolates with an rpoB Ser531Leu and 
His526Tyr mutation (J du Plessis, M.Sc thesis 2013).  
The results of the current study complement the findings of previous work in our lab; here it 
was demonstrated that verapamil has a larger effect on M. tuberculosis clinical isolates 
harbouring an rpoB Ser531Leu mutation compared to an rpoB His526Tyr. Verapamil restored 
susceptibility to rifampicin (at 10μg/ml) by up to 72% in a rifampicin mono-resistant isolate, 
and 47% in an MDR isolate harbouring an rpoB ser531Leu mutation. Conversely, 
susceptibility was only restored by up to 13% in a rifampicin mono-resistant isolate harbouring 
an rpoB His526Tyr mutation, while no restoration was observed in the MDR isolate.  
When considering M. tuberculosis paired isolates from a single patient, it was observed that 
there is a large difference in response to verapamil, especially in the case of patient 1 where 
verapamil decreases the rifampicin MIC by 4-fold in the rifampicin mono-resistant isolate, but 
only results in a 2-fold decrease in the paired MDR isolate. Subsequent gene expression 
analysis comparing the expression levels of six efflux pump genes between the rifampicin 
mono-resistant and MDR isolate revealed no statistically significant differential expression. 
However, in patient 1 five of the six efflux pump genes investigated showed to be up-regulated 
by less than 2-fold. Two of the genes investigated in patient 2 showed a fold change greater 
than 2, but with no statistical significance. When considering the number of efflux pumps 
encoded for by the M. tuberculosis genome it may be possible to hypothesise that there may be 
a biological significance if numerous efflux pumps are differentially expressed. A biological 




effect of a larger scale of efflux pumps being up-regulated may account for the difference 
observed between the rifampicin mono-resistant and MDR isolate. A whole transcriptome 
approach would be beneficial for understanding the differences observed between the paired 
rifampicin mono-resistant and MDR isolates, especially considering that whole genome 
sequencing analysis demonstrated no genetic difference between these isolates which may 
account for the phenotypic difference observed (Chapter 4). 
To further investigate the differential response to verapamil observed between the initial 
isolates selected with different rpoB mutations, the rifampicin MIC was determined for a larger 
sample set. Since the isolate harbouring a Ser531Leu mutation was a Beijing isolate, and the 
His526Tyr isolate was from the EAI lineage, the new isolates selected represent a paired isolate 
for each lineage i.e. and additional Beijing isolate with an rpoB His526Tyr and an EAI isolate 
with a Ser531Leu mutation were selected. This allowed for the determination of either genetic 
background or rpoB mutation as a causative mechanism for the observed differential response. 
In addition a LCC isolate with an rpoB Ser531Leu mutation was selected. Our results 
confirmed that the differential response to verapamil was in fact due to a difference in rpoB 
mutation, and was independent of genetic background. Verapamil was shown to be more 
effective on M. tuberculosis isolates harbouring an rpoB Ser531Leu mutation. This finding was 
subsequently confirmed using in vitro generated rpoB mutants originating from the same 
progenitor, with a “clean” genetic background. It can therefore be concluded that additional 
genetic changes are not contributing to the observed phenotype.  
Numerous studies investigating efflux pump activity have been done in M. tuberculosis isolates 
with different rpoB mutations. These studies demonstrated the role of efflux pumps in defining 
the level of resistance or causing drug tolerance in M. tuberculosis isolates with rpoB 
Ser531Leu or rpoB His526Tyr using efflux pump inhibitors such as verapamil to confirm the 
role of drug efflux. However, this is the first study demonstrating a difference in response to 
verapamil treatment between isolates with different rpoB mutations. The causative mechanism 
of this observed difference is however unknown. Future studies such as whole transcriptomic 
and proteomic analysis may be able to identify differential expression of genes involved in this 
response and identify the mechanism of the increase sensitivity of rpoB Ser531Leu mutants to 
verapamil. This study demonstrated that in both the in vitro generated mutants efflux pump 
genes were down-regulated which does not correlate to the efficacy of an efflux pump inhibitor. 
This suggests that the efflux pump activity is activated by the presence of rifampicin. This 




hypothesis is supported by numerous studies were efflux pump genes have been shown to be 
up-regulated in response to rifampicin exposure, reviewed in Chapter 2 (4). However, that lack 
of up-regulation between the rifampicin mono-resistant in vitro mutants and their pan-
susceptible progenitor is a unique finding since studies have demonstrated differential efflux 
pump gene expression between sensitive and MDR M. tuberculosis clinical isolates (23). 
However, in vitro generated mutants may differ from clinical resistant isolates since M. 
tuberculosis was not exposed to host pressure and additional anti-TB drugs during the selection 
of the resistant mutant. Again, only a select number of genes were analysed and a whole 
transcriptomic approach may reveal a more prominent pattern since there are numerous efflux 
pumps encoded by the mycobacterial genome.  
An additional limitation of this study is that only one anti-TB drug was investigated as a model. 
It is unknown whether the observed response to verapamil based on the rpoB mutation will 
carry through to other anti-TB drugs. This is important to consider since efflux based 
mechanisms have been shown to contribute to bedaquiline resistance and subsequent cross–
resistance to clofazamine (14, 17). Bedaquiline is currently used as a treatment option for MDR 
patients who are already harbouring an rpoB mutation. If the effects observed in this study, as 
a result of rpoB mutation types, extend to the efflux activity associated with bedaquiline and 
clofazamine resistance levels, there may be serious consequences for treatment outcomes.   
In conclusion, this study confirmed the contribution of efflux pump activity to rifampicin 
resistance in M. tuberculosis by demonstrating a change in the level of resistance in response 
to efflux pump inhibitor verapamil. In addition this study showed a difference in the response 
of M. tuberculosis isolates with different rpoB mutations to verapamil treatment. This finding 
may have implications for the consideration of the inclusion of efflux pump inhibitors in 
treatment regimens. Inclusion of verapamil may be less efficient when treating isolates with an 
rpoB His526Tyr mutant, depending on the concentrations used. It has been observed that it is 
unclear if the amount of verapamil used in in vitro studies is attainable in patients undergoing 
treatment (11).  It may be important to consider this since verapamil is known to have negative 
side effects on patients who do not suffer from cardiovascular problems.  
However verapamil is still a valuable treatment option for M. tuberculosis since it may inhibit 
efflux-induced tolerance which provides a stable environment for the development of 
resistance causing mutations (12, 13, 31). This study highlights the delayed onset of growth of 
M. tuberculosis in the presence of verapamil. 
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It has previously been commonly understood that mutations in the rifampicin resistance 
determining region (RRDR) of the rpoB gene (encoding RNA polymerase) are the sole cause 
of rifampicin resistance in Mycobacterium tuberculosis and the level of drug resistance may 
correlate to specific rpoB mutations (1, 2). This view of drug resistance in general, and more 
specifically rifampicin resistance has changed in recent years with an increasing amount of 
studies focusing on the contribution of efflux pump systems to drug resistance. The use of 
efflux pump inhibitors, as well as gene expression analysis in response to anti-TB drug 
exposure is frequently used to investigate the role of efflux pumps in drug resistance, 
identifying the involvement of numerous pumps in rifampicin resistance (3). For example, over 
expression of Rv1258c has been associated with resistance to isoniazid, rifampicin, 
ethambutol, ofloxacin and β-lactams while over-expression of the Rv0559c-Rv0560c gene 
cluster has been associated with rifampicin resistance (4–6). Studies using efflux pump 
inhibitors have implicated drug efflux in resistance to compounds such as rifampicin, isoniazid 
and ofloxacin (7–10). More recently, studies with efflux pump inhibitor verapamil have 
implicated drug efflux in cross resistance to clofazamine and bedaquiline (11, 12). 
Previous studies in our group have demonstrated that closely related M. tuberculosis isolates 
harboring the same rpoB mutations displayed a wide range of minimum inhibitory 
concentrations; efflux pumps were shown to be involved in defining the level of rifampicin 
resistance (9). Subsequent investigation into the proteomic response to rifampicin exposure 
identified an array of proteins up-regulated in response to rifampicin (Figure 6.1) (M.Sc Thesis, 
Margaretha Bester).  
From Figure 6.1 it is evident that proteins involved in energy metabolism were differentially 
expressed in response to rifampicin exposure. Of particular interest were the AtpA and AtpH 
subunits of the F1F0-ATP synthase. In a separate proteomic study the AtpA and AtpB subunits 
were shown to be up-regulated in response to ethambutol treatment in M. smegmatis (13) 
confirming the involvement of this enzyme in response to antibiotic exposure. This enzyme is 
the final enzyme involved in the production of ATP in mycobacteria (14) and is of particular 
interest as a drug target in M. tuberculosis. Along with AtpA and AtpB, cytochrome c oxidase 
has also been to be up-regulated in response to ethambutol exposure (13). 
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Figure 6.1 Differentially regulated proteins in response to rifampicin exposure in M. tuberculosis 
closely related clinical isolates (M.Sc Thesis, Margaretha Bester). 
F1F0-ATP synthase is a unique target for bedaquiline, the first new anti-TB treatment approved 
by the FDA in 40 years (15). Bedaquiline has many desirable qualities, including decreased 
time to smear conversion of MDR-TB cases, a lack of cross resistance to current first-line anti-
TB drugs, in vitro activity again resistant and sensitive isolates, as well as against non-
replicating bacilli (16–19).  
Beyond the role of the F1F0-ATP synthase as a drug target, it is important to investigate this 
and other components involved in energy metabolism since both ATP and the proton motive 
force are driving factors of efflux pumps (3). Components involved in the production of energy 
metabolism are attractive drug targets due to their essentiality for survival, as well as their role 
in fuelling efflux pumps. It is therefore important to ascertain the role of energy metabolism as 
well as drug efflux in drug resistant. 
6.2. Hypothesis 
Rifampicin exposure induces a signalling cascade in rifampicin resistant M. tuberculosis 
isolates which culminates in the up-regulation of numerous genes such as those encoding efflux 
pumps as well as those encoding components involved in energy metabolism.  










1. To define the response of components 
involved in energy metabolism in M. 
tuberculosis to rifampicin exposure.





components involved in 
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2.To determine the influence of rifampicin 
exposure on the expression of a panel of 
efflux pumps in M. tuberculosis.
6.3. Aims 
This study aims to investigate the role of energy metabolism and drug efflux in rifampicin 
resistant M. tuberculosis clinical isolates. 
Specific aims: 
1. To determine the expression levels of components involved in energy metabolism 
genes in response to rifampicin exposure in rifampicin resistant M. tuberculosis clinical 
isolates. 
2. To determine the expression levels of a subset of efflux pump genes in response to 
rifampicin exposure in rifampicin resistant M. tuberculosis clinical isolates. 
6.4. Experimental approach 
Methods used in this study have been detailed in Chapter 3. The experimental approach 


















6.5. Results  
6.5.1 RNA extraction and quality assessment 
In order to characterize the growth characteristics of the individual M. tuberculosis isolates, 
growth curves were plotted to determine the number of days required for each isolate to reach 
mid-log phase following a standard inoculum (Figure 6.3). This analysis showed that there was 
no significant difference in growth characteristics of the different isolates during log phase. 
However, the OD600 readings decrease after day 14 for isolates R912 and R1210 due to the 
formation of clumps in the liquid culture. Mid-log phase was defined by an OD600 of 0.8.  
 
Figure 6.3 Growth curves for M. tuberculosis isolates used in this study. Error bars denote standard 
deviation between duplicate experiments.  
In order to determine the transcriptional response of a panel of efflux pump and energy 
metabolism genes to rifampicin exposure mid-log M. tuberculosis cultures were exposed to 
rifampicin at a concentration equivalent to ¼ MIC for each isolate (determined in Chapter 5, 
Table 5.2). M. tuberculosis isolates were exposed for a period of 24 hours before RNA was 
extracted. An unexposed control (cultured in the absence of rifampicin) was included for each 
isolate.  
Following DNAse treatment, the RNA samples were subjected to PCR analysis to ensure there 
was no residual DNA (Figure 6.4 A). No PCR products were present on the gel confirming the 






























absence of DNA contamination. Subsequently the integrity of the isolated RNA as well and 
the concentration of RNA was assessed using the Bioanalyser. Figure 6.4 B shows a 








Figure 6.4 RNA quality assessment. Representative Bioanalyser fractionation of RNA samples 
indicating the presence of 16S and 23S RNA. Lane 1: Ladder, lanes 2 to 5: DNAse treated RNA 
samples. 
6.5.2. The response of components involved in energy metabolisms to 24 hours rifampicin 
exposure in M. tuberculosis clinical isolates 
Representative genes from various components involved in energy metabolism were evaluated 
with RT-qPCR to determine whether rifampicin exposure altered the level of expression of 
these selected genes (Table 6.1). The energy metabolism components evaluated included the 
F1F0-ATP synthase (atpA), succincate dehydrogenase (sdhA), bc1 cytochrome reductase 
(qcrC), aa3 cytochrome c oxidase (ctaD), NADH dehydrogenase (nuoA) and MenA (menA) 
(involved in menaquinone biosynthesis). Genes were considered to be significantly 
differentially expressed if they were differentially expressed by a factor of 2-fold or more 
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Table 6.1 Differential gene expression in response to rifampicin exposure of components involved in 
energy metabolism in M. tuberculosis. 








 R721 R807 R912 R1210 
atpA -1.25599 -1.13506 1.042479 -0.43952 
sdhA -0.33717 -1.03303 1.042971 1.207413 
qcrC -1.47021 -1.49675 -1.05158 -1.20143 
ctaD -1.08467 0.018845 1.085799 -0.53016 
nuoA 1.081016 -1.32605 1.077796 -1.02839 
menA 1.090646 -1.67803 0.01951 -0.76938 
This study shows no differential response in gene expression between isolates from different 
lineages or with different drug resistance profiles, indicating that the components involved in 
the electron transport chain and therefore energy metabolism are not influenced at the level of 
transcription in these M. tuberculosis isolates in response to rifampicin exposure at a 
concentration of ¼ MIC.   
6.5.3. The response of efflux pump genes to 24 hours rifampicin exposure in M. 
tuberculosis clinical isolates 
A panel of efflux pump genes were evaluated with RT-qPCR to identify differential gene 
expression in response to rifampicin exposure (Table 6.3). The characteristics of the efflux 
pumps evaluated are shown in Table 6.2. Genes were considered to be significantly 
differentially expressed if they were differentially expressed by a factor of 2-fold or more 









Table 6.2 Characteristics of selected efflux pumps for the investigation into the transcriptional response 
to rifampicin exposure in M. tuberculosis.  
Efflux pump Gene Desription Transporter family 
EmrB Rv0783 Possible multidrug resistance integral membrane 
efflux protein EmrB 
MFS 
Rv3728 Rv3728 Conserved two-domain membrane protein MFS 
PstB Rv0933 Phosphate transport ATP-binding protein ABC 
DrrA Rv2936 Daunorubicin-dim (dimycocerosate) transport 
ATP-binding protein 
ABC 
bacA Rv1819c Drug transport transmembrane ATP-binding 
protein, vitamin B12 
ABC 
mmpL5 Rv0676c Probable conserved transmembrane transport 
protein MmpL5 
RND 
For the majority of the efflux pumps investigated in this study, no differential expression was 
observed in response to rifampicin exposure. However mmpL5 was significantly up-regulated 
in all M. tuberculosis isolates independent of their genetic background, namely Beijing or EAI. 
mmpL5 was up-regulated in both rifampicin mono-resistant and MDR isolates.  
Table 6.3 Differential gene expression of efflux pump genes in M. tuberculosis in response to 
rifampicin exposure. 








 R721 R807 R912 R1210 
EmrB 0.315294 -1.35808 -0.66023 1.96942 
Rv3728 0.588727 -0.05518 -0.4481 0.994989 
PstB 0.365759 -1.30298 -0.51266 -0.05814 
DrrA 0.001703 -1.21936 -1.20799 1.216266 
bacA -1.21698 -1.30537 -0.38066 -1.2373 
mmpL5 10.62143* 7.363803* 5.082641* 10.7345* 
*Significant differential expression 




Whole genome sequencing data was available for all isolates used in this study and was 
therefore used to determine if genomic changes could explain the results observed in Table 6.3. 
The upstream regions of each efflux pumps gene was investigated for the presence of 
polymorphisms which may influence the regulation of each gene. No polymorphisms were 
observed in any of the putative promoter regions investigated in this study. In addition, the 
efflux pump genes were investigated for the presence of polymorphisms which may influence 
the activity of the candidate efflux pumps (Table 6.4). 
The genome sequences of the Beijing isolates (R721 and R807) (originating from a single 
patient) showed polymorphisms in two efflux pump encoding genes, bacA and mmpL5. 
Similarly, the genome sequences of the EAI isolates (R912 and R1210) identified 
polymorphism in four of the six efflux pump encoding genes investigated in this study, namely 
Rv3728, DrrA, bacA and mmpL5. The polymorphisms occurring in bacA are not the same 
between the isolates from different genetic backgrounds. The mmpL5 gene showed to have the 
same polymorphism in all four isolates used in this study. It is unknown whether these 
polymorphisms influence the activity of the efflux pumps. 









R721 R807 R912 R1210 
EmrB - - - - 
Rv3728 - - Ala608Thr Ala608Thr 
PstB - - - - 
DrrA - - His309Asp His309Asp 
bacA Trp153Ser Trp153Ser Ile603Val Ile603Val 
mmpL5 Ile948Val Ile948Val Ile948Val Ile948Val 
The Department of Biomedical Sciences has a genome bank of approximately 400 M. 
tuberculosis clinical isolates (at the time of submission) which have been whole genome 
sequenced. This collection includes both drug sensitive and resistant isolates. The 
polymorphisms identified in this study in efflux pump genes (relative to M. tuberculosis 
H47Rv) (Table 6.4) were investigated in this genome bank to determine the possible clinical 




relevance of polymorphisms in these genes. The polymorphisms identified in mmpL5 
(Ile948Val) and bacA (Trp153Ser) were present in 330 and 13 isolates, respectively. These 
polymorphisms occurred in both drug sensitive and resistance isolate indicating that they are 
not involved in drug resistance. The remaining polymorphisms identified in R912 and R1210 
were shown to be present in an additional 5 M. tuberculosis isolates, all of which belong to the 
EAI lineage, indicating that this polymorphism may be a phylogenetic marker. 
Together these results indicate mmpL5 is significantly up-regulated in response to rifampicin 
exposure in both rifampicin mono-resistant and MDR isolates from different genetic 
backgrounds. EmrB, Rv3728, PstB, DrrA and bacA were not significantly differentially 
expressed in response to rifampicin expose. The up-regulation of mmpL5 confirms that the 
rifampicin exposure influences gene expression and that the absence of differential expression 
in the energy metabolism genes and the remaining efflux pump genes was not due to 
experimental error.  
6.5.4. Investigation into transcriptional regulators associated with the candidate efflux 
pumps in this study 
Recent ChIP-Seq technology has allowed for the identification of putative regulatory 
interactors for numerous genes in M. tuberculosis. The data generated from this experiment 
was used to identify predicted regulatory interactors of the efflux pump genes investigated in 
the study (Table 6.5). Many transcriptional regulators were identified to interact with each 












Table 6.5 Predicted regulatory interactors for efflux pumps in M. tuberculosis. 
Efflux pump Predicted regulatory interactors 
EmrB Rv0023, Rv0757, Rv0767c, Rv0967, Rv1033c, Rv1404, Rv1816 
Rv3728 
Rv0023, Rv0047c, Rv0081, Rv0135c, Rv1033c, Rv1353c, Rv1990c, 
Rv2021c, Rv2034, Rv2250c, Rv2324, Rv2506, Rv3736 
PstB Rv0081, Rv0967, Rv1816 
DrrA 
Rv0023, Rv0047c, Rv0135c, Rv0273c, Rv0302, Rv0757, Rv0767c, 
Rv0967, Rv1353c, Rv1473A, Rv1556, Rv1719, Rv1816, Rv2034, 
Rv2887, Rv2989, Rv3219, Rv3597c 
bacA Rv0081, Rv0324, Rv1816, Rv3133c, Rv3574, Rv3597 
mmpL5 
Rv0047c, Rv0081, Rv0678, Rv0691c, Rv0967, Rv1473A, Rv1719, 
Rv2011c, Rv3133c, Rv3249c, Rv3597c, Rv3736 
The genomes for each isolate used in this study were subsequently investigated to identify 
polymorphisms in the predicted regulatory interactors identified in Table 6.5. For R721 and 
R807 polymorphisms were identified in three candidate transcriptional regulator encoding 
genes, namely Rv0324, Rv0302 and Rv1719 (Table 6.6). Polymorphisms were also identified 
in three candidate transcriptional regulator encoding genes in R912 and R1210, namely 
Rv1816, Rv0324 and Rv3736 (Table 6.6). A polymorphism in one candidate transcriptional 
regulator, Rv0324, was present in all four isolates in the study.    











R721 R807 R912 R1210 
Rv1816 - - Leu191Arg Leu191Arg 
Rv3736 - - Gly144Arg Gly144Arg 
Rv0324 Thr168Ala Thr168Ala Thr168Ala Thr168Ala 
Rv0302 His84Asp His84Asp - - 
Rv1719 Asp104Tyr Asp104Tyr - - 
The presence of polymorphisms in candidate transcriptional regulators (Table 6.6) suggests 
that the transcriptional regulators may have altered function and depending on the response of 
their predicted interactors (Table 6.7) to rifampicin, it may be possible to associate a 




transcriptional regulator with the response of M. tuberculosis to rifampicin exposure. However, 
these may also represent phylogenetic markers. A larger subset of isolates would need to be 
investigated to determine the role of these polymorphisms. Rv1816 and Rv0302 are classified 
as transcriptional repressors, while Rv3736 is a transcriptional activator. Rv0324 and Rv1719 
may act as a transcriptional activator or repressor (http://genolist.pasteur.fr/TubercuList/; The 
Pfam protein families database (20)). 
Table 6.7 Efflux pumps predicted to interact with candidate transcriptional regulators observed to have 












Rv1816 TetR Repressor 






Activator mmpL5, Rv3728 R912; R1210 




R721; R807; R912; 
R1210 
Rv0302 TetR/acrR Repressor DrrA R721; R807 
Rv1719 




mmpL5, Rv3728 R721; R807 
This study identified five predicted transcriptional interactors of interest. Each transcriptional 
regulator contained a polymorphism which may influence its regulatory activity, and therefore 
play a role in the response to rifampicin exposure.  
6.6. Discussion 
Numerous previous studies in our group have investigated the mechanisms involved in defining 
the level of rifampicin resistance in M. tuberculosis. Findings of these studies culminated in 
the hypothesis that exposure of rifampicin resistant M. tuberculosis isolates to rifampicin 
results in the activation of signalling response pathways which cause an up-regulation of 
numerous efflux pump genes and the F1F0-ATP synthase.  




Previous work demonstrated an up-regulation of the AtpA and AtpH proteins in response to 
rifampicin exposure in M. tuberculosis clinical isolates. The AtpA and AtpH for part of the 
F1F0-ATP synthase enzyme, the final enzyme involved in oxidative phosphorylation and is 
responsible for the conversion of electrochemical potential energy generated by the proton 
motive force into chemical energy in the form of ATP phosphoanhydride bonds (3, 21, 22). 
However, it can be assumed that an up-regulation in the amount of protein encoding the final 
enzyme involved in energy metabolism may impose a pressure on the cell to up-regulate other 
components involved in energy metabolism to ensure optimisation of the whole system since 
energy production is not a single step process. Therefore numerous genes involved in energy 
metabolism in M. tuberculosis were selected as candidates for this study.  
Our investigation into the response of components involved in energy metabolism to rifampicin 
exposure demonstrated that there was no significant differential expression of genes involved 
in energy metabolism in M. tuberculosis. This included the atpA gene, encoding the AtpA 
subunit which was previously shown to be up-regulated in response to rifampicin exposure 
(M.Sc Thesis, Margaretha Bester). This discrepant result may be attributed to post-
transcriptional processing. An increase in protein abundance may not equate to an increase in 
gene expression; numerous studies in other organisms have noted a negative correlation 
between mRNA and protein abundance (23). Negative correlation has been attributed to the 
extended half–life of proteins; as well difference in post-transcriptional processing and 
regulation (23, 24). In addition, it has been highlighted that the synthesis and degradation of 
mRNA transcripts need to be better understood to understand the correlation between mRNA 
and protein abundance (24). 
In addition to the atpA gene, no significant differential expression of components involved in 
energy metabolism in M. tuberculosis was observed in response to rifampicin exposure. 
Together these results indicate the level of transcription of genes involved in energy 
metabolism was not altered in response to rifampicin exposure. However, this does not rule out 
an increase in flux through the electron transport chain. The activity of F1F0-ATP synthase has 
previously been shown to be regulated by the presence of inhibitor ADP. In addition it has been 
noted that a change in the proton motive force correlates with a change in enzyme activity (22). 
Considering this, and the findings of this study it may be more beneficial to investigate the 
levels of ATP or the NADH/NAD+ ratios in response to rifampicin exposure to better 
understand the influence of this anti-TB drug on energy metabolism. In addition, understanding 




the response of ATP levels and NADH/NAH+ ratios to drug exposure may allow for a better 
understanding of efflux pump activity considering that efflux pumps largely rely on ATP 
hydrolysis or the proton motive force for functioning (discussed in Chapter 2) (3).  
Of the six efflux pump genes investigated in this study, only mmpL5 was observed to be up-
regulated in response to rifampicin exposure (Table 6.3). This up-regulation was observed 
across all isolates used in this study, however there was no significant difference between the 
level of expression in rifampicin mono-resistant and MDR isolates. The same observation was 
made when comparing between isolates of different lineages. This suggests that the up-
regulation of mmpL5 in response to rifampicin exposure is a general occurrence, not limited to 
specific M. tuberculosis genetic backgrounds. The mmpL5 gene encodes a probable conserved 
membrane transport protein of the same name, and is a member of the 
resistance/nodulation/cell division (RND) family of transporters (25). This membrane protein 
forms an efflux system with a protein encoded by an adjacent gene, mmpS5. This mmpS5-
mmpL5 efflux system has previously been associated with azole resistance, but more recently 
has been associated with bedaquiline resistance (11, 25). In addition, over-expression of this 
efflux pump system has been demonstrated to be the causal mechanism of cross resistance 
between bedaquiline and clofazamine, a renewed drug of interest for TB treatment (11, 26). 
Over-expression of the mmpS5-mmpL5 efflux system and the subsequent increase in resistance 
levels to these compounds is due to a mutation in a repressor of the genes encoding these 
proteins, Rv0678 (11, 25, 26). Whole genome sequencing of the M. tuberculosis isolates used 
in study revealed no mutation in the gene encoding this repressor, suggesting the presence of 
alternate regulatory mechanisms for this efflux pump system. Indeed, ChIP-seq analysis has 
identified an additional 12 predicted regulatory interactors for mmpL5. Due to the importance 
of bedaquiline in treatment of MDR and XDR infection, as well its ability to shorten treatment 
periods it is important to further investigate the efflux based resistance mechanism (17, 19, 27, 
28). Identification of additional mutations in regulators of this efflux system is vital for the 
development or rapid genotypic diagnostic tests. While efflux based cross-resistance has been 
demonstrated between bedaquiline and clofazamine, no studies have investigated cross 
resistance between first-line anti-TB drugs and bedaquiline and /or clofazamine. Initial studies 
into the efficacy of bedaquiline demonstrated no cross-resistance between first-line drugs and 
bedaquiline with respect to mode of action and resistance causing mutations i.e. M. tuberculosis 
isolates resistant to first-line drugs did not develop bedaquiline resistance at a higher rate than 
pan-susceptible isolates (16, 17). Additionally susceptibility testing of a clofazamine resistant 




mutant (due to an Rv0678 mutation) demonstrated no cross resistance with rifampicin (11). 
Together these findings suggest an alternate regulatory pathway to be involved in the up-
regulation of mmpL5 in response to rifampicin exposure.  
Interestingly, while mmpL5 was observed to be up-regulated, none of the other efflux pump 
encoding genes investigated in this study showed a significant response to rifampicin exposure. 
The efflux pump genes investigated in this study have previously differentially expressed in 
response to rifampicin exposure. For example, Rv3728 was shown to be up-regulated 2-fold in 
response to rifampicin exposure at ½ MIC in 3 out of 5 M. tuberculosis isolates investigated 
(29). In addition drrA and pstB differential expression was observed in response to sub-
inhibitory concentrations of rifampicin (30–32). It is therefore possible that the rifampicin 
concentration used in this study (¼ MIC) was not sufficient to elicit a response. This may be 
an important observation since depending on the MIC of specific M. tuberculosis isolates, 
during infection M. tuberculosis may never be exposed to a rifampicin concentration as high 
½ MIC. bacA was demonstrated to be up-regulated in response to rifampicin in the same study, 
under the same conditions. In a separate study bacA was shown to be up-regulated by exposure 
to ¼ MIC (33); however our study did not show the same response.  
To investigate these results further, available ChIP-seq data was used to identify predicted 
regulatory interactors for each of the efflux pump encoding genes used in this study (Table 
6.5). Whole genome sequence data for the M. tuberculosis isolates used in this study was 
subsequently used to indentify polymorphisms in the predicted regulatory interactors. 
Polymorphisms were identified in six of the predicted interactors (Table 6.6) however only one 
predicted regulator was observed to have a mutation in all M. tuberculosis isolates used in this 
study. Rv0324 is a probable transcriptional regulator belonging to the ArsR family of 
transcriptional activators and repressors (http://genolist.pasteur.fr/TubercuList/; The Pfam 
protein families database). Based on the observed up-regulation of bacA in response to 
rifampicin exposure in literature, and the absence of up-regulation in the isolate used in this 
study containing a polymorphism in a predicted regulator of bacA this study proposes that 
Rv0324 may acts as a transcriptional activator in response to rifampicin exposure (Figure 6. 
5).  
We propose a model whereby in response to rifampicin exposure transcriptional regulator 
Rv0324 binds to bacA, up-regulating bacA expression resulting in an increase in the amount of 
BacA ABC transporter in the cell membrane and a subsequent increase in the efflux of 




rifampicin from the cell (Figure 6.5A). In the case of the isolates used in this study, a 
polymorphism prevents the activation of BacA by Rv0324 and no up-regulation of this gene is 
observed in response to rifampicin exposure (Figure 6.5B).   
Further investigation into the genomes available in the Department of Biomedical Sciences 
identified the Thr168Ala polymorphism in Rv0324 to be present in 321 M. tuberculosis clinical 
isolates, 57 of which were susceptible. In order to confirm the hypothesis that the 
polymorphism in Rv0324 prevents the activation of expression of bacA in response to 
rifampicin exposure futures studies include investigating the response of bacA to rifampicin 
exposure in numerous isolates which have a wild type Rv0324 gene. An additional finding in 
literature is that while bacA is over-expressed in response to rifampicin exposure, a bacA 
deficient M. tuberculosis mutant demonstrated no change in sensitivity to rifampicin (34). This 
indicates that bacA is not responsible for contributing to the level of rifampicin resistance, but 
the expression thereof is altered in the presence of drug.  
While the response to rifampicin observed in this study was minimal, only a small subset of 
genes was analysed. More information may be acquired with an RNA-seq experiment, where 
all genes differentially expressed in response to rifampicin exposure may be observed. In 
addition, a limitation of this study was the small sample size; only four M. tuberculosis isolates 
were investigated. A larger study where a range of rifampicin concentrations are used may also 
shed light on the discrepant results seen between this study (where ¼ MIC was used) and those 
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Figure 6.5 Schematic representation of the proposed regulation of bacA in response to rifampicin 
exposure in M. tuberculosis. In the presence of rifampicin Rv0324 activates transcription of bacA 
resulting in increased expression of this gene and subsequently an increase in the amount of BacA 
deposited in the cell membrane (A). In the case of a polymorphism in Rv0324, bacA expression remains 
unchanged as does the amount of ABC transporter deposited in the cell membrane (B).  
In conclusion, this study is the first to demonstrate the up-regulation of mmpL5 in response to 
rifampicin exposure. Furthermore a putative transcriptional regulator acting in response to 
rifampicin exposure was identified. A model for the response to rifampicin exposure has been 
proposed, however further studies are needed to substantiate this hypothesis. 
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This study aimed to investigate mechanisms contributing to drug resistance in M. tuberculosis 
by focusing on three main aspects namely: the in vivo evolution of drug resistance from 
rifampicin mono-resistance to multi-drug resistance (MDR), the role of efflux pumps in 
rifampicin resistance with a specific focus on the effect of rpoB mutations on the response to 
efflux pump inhibitor verapamil and lastly, the response of energy metabolism and efflux pump 
genes to rifampicin exposure.  
Interrogation of the strain bank housed in the Department of Biomedical Sciences allowed for 
the identification of individual patients with multiple samples present in the strain bank which 
demonstrate potential evolutionary patterns with respect to drug resistance i.e. numerous drug 
resistance evolution patterns. This is an important resource which may be used for future 
studies to further investigate the in vivo evolution of drug resistant in M. tuberculosis. This 
study investigated a small subset of the available samples, representing the evolution of MDR 
from rifampicin mono-resistance. A total of 6 isolates originating from 3 patients were 
identified and confirmed to have evolved MDR during the course of treatment. Whole genome 
sequencing successfully demonstrated the genome of M. tuberculosis is dynamic during the 
course of infection, with numerous genetic changes emerging and disappearing between 2 time 
points. This finding challenges available literature which has shown the stability of the M. 
tuberculosis genome over time, while supporting more recent findings that the M. tuberculosis 
genome is highly dynamic and diverse (1–7). In addition, deep sequencing allowed for the 
identification of sub-populations present within a patient at a given time point, highlighting the 
capacity of deep sequencing. This finding has implications when considering the design of 
rapid genotypic diagnostics. For instance, current genetic testing may not be sensitive enough 
to detect an rpoB mutation present in only 10% of the population and when put on standard 
first-line treatment a patient infected with this isolate would have a high likelihood of 
developing rifampicin resistance, weakening the 4 drug regimen. Deep sequencing 
technologies should therefore be exploited for the design of new diagnostic tests. This 
conclusion is complementary to recent commentaries based on whole genome sequencing 
studies (7, 8). 
However, this study was limited by the small number of available samples confirmed to 
demonstrate evolution of resistance from rifampicin mono-resistance to MDR. Future studies 
include deep sequencing of a larger sub-set of samples demonstrating evolution of drug 
resistance from MDR to pre-extensively drug resistant (XDR) and XDR. In addition, whole 




genome sequencing will be coupled with whole proteomic analysis to investigate the 
physiological consequences of any genetic changes observed.  
This study went on to investigate the role of efflux pump activity in rifampicin resistance, 
focusing on the effect of rpoB mutations on the response to verapamil treatment. It was 
demonstrated that verapamil has a differential effect on M. tuberculosis isolates with different 
rpoB mutations. M. tuberculosis isolates with an rpoB Ser531Leu mutation causing rifampicin 
resistance were more susceptible to verapamil treatment when compared to an isolate with an 
rpoB His526Tyr mutation. These findings suggest differential efflux pump activity between 
isolates however RT-qPCR was unable to identify substantial differential expression of efflux 
pump genes accounting for this response. Future studies include whole transcriptomic and/or 
proteomic analysis to identify proteins or regulatory pathways altered by the presence of 
different rpoB mutations. The differential response to verapamil observed due to the presence 
of different rpoB mutations highlights the importance of personalised treatment. Considering 
potential side-effects of verapamil on patients with no cardiovascular problems, it may be 
important to determine if an M. tuberculosis isolate will sufficiently respond to verapamil 
treatment. Additional studies are needed to determine if the presence of specific rpoB mutations 
will influence the use of verapamil to counter act the efflux mediated level of resistance to 
bedaquiline and clofazamine. Recent studies have highlighted the concurrent use of verapamil 
and bedaquiline to potentiate bedaquiline treatment. It has also been suggested that since 
verapamil lowers the MIC of bedaquiline, lower concentrations may potentially be considered 
to diminish the toxic effect of treatment (9, 10). The findings of this study should serve as the 
basis for future studies to investigate the importance of the pathogens genetic background on 
the efficacy of inhibitor treatment.  
Lastly, this study investigated the response of M. tuberculosis to rifampicin exposure. This 
study demonstrated that in response to rifampicin exposure there is no significant change in 
gene expression of selected components involved in energy metabolism in M. tuberculosis. In 
addition, little change was seen in response to rifampicin exposure with regards to efflux pump 
expression. This may be due to the concentration of rifampicin used; previous studies used sub-
inhibitory concentrations of rifampicin (½ MIC). In addition, our study only investigated a 
small subset of efflux pump genes. Furthermore, gene expression analysis is not a measure of 
efflux pump activity, or flux through energy metabolism pathways. Future studies involve 
measuring the presence of metabolites in response to drug exposure e.g. measuring the levels 




of cellular ATP or the NADH/NAD+ ratios. In addition future studies include investigating the 
response to rifampicin exposure using whole transcriptomic and proteomic analysis.  
While little response to rifampicin exposure was observed, mmpL5 was shown to be 
significantly up-regulated in response to rifampicin exposure. This is the first study to show 
the response of this gene to rifampicin exposure. This gene encodes the mmpL5 protein, 
forming part of the mmpS5-mmpL5 efflux system, recently associated with bedaquiline and 
clofazamine resistance (9, 11). This efflux based resistance mechanism is founded on the 
presence of a mutation in the Rv0678 repressor of this efflux system (9, 11). Susceptibility 
testing of a clofazamine resistant mutant (due to an Rv0678 mutation) demonstrated no cross 
resistance with rifampicin (11). The M. tuberculosis isolates in this study did not have any 
mutations in this repressor, indicating a different regulatory pathway is responsible for the 
response of mmpL5 to rifampicin exposure. Future studies include elucidating if the response 
of this efflux pump to rifampicin exposure is associated with rifampicin resistance, or if this 
up-regulation serves a different metabolomic purpose since this efflux system has been 
proposed to be involved in iron acquisition (11).  
In addition, this study identified a predicted transcriptional regulator of the BacA efflux pump. 
We propose that transcriptional regulator Rv0324 may be involved in the response to 
rifampicin exposure, based on the observation that M. tuberculosis isolates in this study with a 
mutation in this regulator showed no up-regulation of bacA, which has been shown in literature 
to be up-regulated in response to rifampicin exposure (12). The response to rifampicin exposure 
of BacA needs to be investigated in M. tuberculosis isolates with and without an Rv0324 
mutation to confirm whether a wild type Rv0234 will respond to rifampicin exposure resulting 
in up-regulation of BacA. In addition, should this hypothesis be found to be true, additional 
interaction partners of this regulator need to be determined to identify a regulatory pathway 
which acts in response to rifampicin exposure.  
In order to identify additional regulatory mechanisms in response to rifampicin exposure, a 
proposed future study is to do a forward genetic screen using transposon mutagenesis. Briefly, 
a library of transposon mutants generated in a rifampicin resistant M. tuberculosis clinical 
isolate (previously generated and housed in the Department of Biomedical Sciences) will be 
exposed to varying concentrations of rifampicin. A negative screen using WGS will allow for 
the identification of genes essential for the response to rifampicin exposure.  




In conclusion this study demonstrated that the M. tuberculosis genome is dynamic during 
infection. This study highlights the importance of coupling phenotypic studies with whole 
genome sequencing analysis. Knowledge of the genome sequences of the M. tuberculosis 
isolates used in this study allowed us to associate the rpoB mutation type to the differential 
response to rifampicin, since no other genetic changes could clearly be associated with this 
observation. This study demonstrated the importance of the rpoB mutation on efflux pump 
activity and the subsequent response to verapamil treatment. In addition this study identified 
mmpL5 to respond to rifampicin exposure; however the consequence of this observation 
remains unknown. A proposed transcriptional regulator responding to rifampicin exposure was 
also identified in this study. A multi-study approach allowed for a broader understanding of 
the mechanisms involved in drug resistance in M. tuberculosis.  
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Solutions and Media 
 
  






4.7g Middlebrooke 7H9 
0.2% Tween 80 
2.5ml glycerol 
900ml water 
  Autoclave to sterilse 
Supplement with 100ml OADC 
 
7H10 Plates 19g Middlebrooke 7H10 
5ml glycerol 
900ml water 
  Autoclave to sterilise 
Supplement with 100ml ADC 
 
Extraction buffer 5% sodium glutamate 
50mM Tris-HCl [pH 7.4] 
25mM EDTA 
 
Proteinase K buffer 5% sodium dodecyl sulfate 






1mM EDTA  
 
GITC 4M guanidium thiocyanate 




















Table A.2.1 M. tuberculosis isolates selected from the strain bank to show evolution from rifampicin 


















R807 531TTG wt 309GTT MDR MDR 
2 




R3552 531TTG -15 wt MDR MDR 



















R1210 526TAC -15 wt MDR MDR 
5 






















R1801 531TTG wt 315ACC MDR MDR 
8 














R1233 531TTG wt 315ACC MDR MDR 








R1191 526TAC -15 wt MDR MDR 
11 





R20213 wt wt wt MDR Sensitive 
12 





R7974 531TTG -15 wt MDR MDR 
13 




R3389 wt wt wt MDR sensitive 
14 




R20743 516GTC wt Wt/295CCG MDR Mix 
15 




R302 516GTC wt 315ACC MDR MDR 
16 





R2081 531TTG wt wt unclassified 
Rifampicin 
mono 













R800 533CCG -15 wt  MDR 
R873 533CCG -15 wt MDR MDR 
19 



























R1932 - - - MDR  









R2387 531TTG -15 wt MDR MDR 
23 




R3806 531TTG -15 wt MDR MDR 
24 




R2581 531TTG -15 wt MDR MDR 
25 








R10359 531TTG -17 wt MDR MDR 
26 




R5196 531TTG -15 wt MDR MDR 
27 




R6866 wt wt wt MDR sensitive 
28 




R16775 wt wt 315ACC MDR INH mono 
29 














R9817 516GTC wt 315AAC MDR MDR 
31 


















rrs embB gyrA pncA  





R721 wt wt wt wt 
Rifampicin 
mono 
R807 wt wt wt wt MDR 
2 
R13112 wt wt wt wt 
Rifampicin 
mono 
R13235 wt wt wt wt 
Rifampicin 
mono 




R912 wt wt wt wt 
Rifampicin 
mono 
R1210 wt wt wt wt MDR 
4 
R12218 wt wt wt wt 
Rifampicin 
mono 




R6264 wt wt wt wt 
Rifampicin 
mono 















R2080 wt wt wt wt 
Rifampicin 
mono 
R2081 wt wt wt wt 
Rifampicin 
mono 




R12390 wt wt wt wt 
Rifampicin 
mono 




R1976 wt wt wt wt 
Rifampicin 
mono 
R2541 wt 306ATA wt wt  
10 
R21542 wt  wt 10CAC Poly resistant 
R21686 wt  wt 10CAC Poly resistant 






1300 C/T & 
1321 G/A & 
1445 C/T 
 91CCG 103TAG 
Mixed 
population 
R2387 1401 A/G wt 94GGC - XDR 
12 
R5608 wt wt wt wt 
Rifampicin 
mono 
R15828 wt wt wt 391 GG ins Poly resistant 
13 
R12681 wt 306GTG wt 97GAT  
R13347 wt 306GTG wt 97GAT  
 
Table A2.3 Rifampicin and isoniazid DST results 
Sample set Isolate name RIF dst (1μg/ml 
RIF) 
INH dst (0.1μg/ml 
INH) 
Classification 
1 R721 R S Rifampicin mono 
R807 R R MDR 
2 R13112 R R MDR 
R13235 R R MDR 
R13855 R R MDR 
3 R912 R S Rifampicin mono 
R1210 R R MDR 
4 R12218 R R MDR 
R12275 R R MDR 
5 R6264 R S Rifampicin mono 
R15213 R R MDR 
6 R2080 R S Rifampicin mono 
R2081 R S Rifampicin mono 
7 R2083 R S Rifampicin mono 
R12390 R S Rifampicin mono 
R12706 R S Rifampicin mono 
R = resistant; S = sensitive 
 
Table A2.4 Spoligotype analysis of M. tuberculosis isolates demonstrating evolution from rifampicin 
mono-resistance to MDR 








R807 MDR  BEIJING 














 X3 (LCC) 

















The figures presented below are a representation of the FastQC results generated for all M. 













Figure A3.1 The distribution of quality scores across all bases. The blue line represents the mean 
quality, the red lines represent median values and the green and red regions of the plot indicate high 

















Figure A3.2 The distribution of quality across all sequences. Score used to assess whether a proportion 
of the sequences have universally low quality scores. 93  





Figure A3.3 Sequence content across all bases. M. tuberculosis is expected to have a high GC content 
 
 
Figure A3.4 Representative of the mean percentage of GC contect across all bases. The horizontal red 
line indicates minimal change in the average GC content for all bases. A GC content of above 60% is 
expected for M. tuberculosis. 





Figure A3.5 The mean distribution of the percentage GC content across all sequences. A normal 
distribution of the GC content is observed with the central peak corresponding to the overall GC content 
of this genome.  
 





Figure A3.6 Sequence duplication levels in the library sequenced. A high pecentage of duplicate 
sequences are present in the Illumina reads, however PCR duplicates are removed during bioinformatic 
analysis. 
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